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Abstract: 
Background: Lung cancer causes the majority of cancer-related deaths in the United States.  
Screening for lung cancer with low dose CT (LDCT) has become a prominent topic.  This 
modality has the potential to contribute to a decrease in lung cancer associated mortality.  
Preliminary data from a large randomized controlled trial have shown a 20% decrease in 
mortality.  Currently, no guidelines endorse LDCT screening for lung cancer.  The harms of 
screening for lung cancer have not been fully characterized in a focused systematic review.   
Purpose: To explore and characterize the harms associated with low dose CT screening for 
lung cancer in high risk populations by evaluating the current evidence.  This information will 
assist policy makers and clinicians as they weigh the risks and benefits of screening high risk 
populations for lung cancer.  
Data Sources: MEDLINE, EMBASE, Cochrane Library, reviews, reference lists, experts 
Study Selection: Studies were included that evaluated low dose screening for lung cancer.  
Those that characterized harms were central to this review.  
Data Extraction: Data were abstracted to abstraction forms. Studies were graded according to 
methods used by the United States Preventive Services Task Force (USPSTF). 
Data Synthesis:  Studies reported variable rates of abnormal results with positivity of 8 to 45%.  
A range of 4 to 55% of total invasive procedures and none to 40% of surgeries were performed 
for benign indications.  Incidental findings were reported in 0.77 to 62% of participants.  Of the 
included studies, 30% discussed anxiety, 55% discussed overdiagnosis, 50% reported morbidity 
and mortality of workup, and 35% reported false negative cases.  False positives at baseline 
ranged from 86 to 98%.  
Limitations: This review included observational studies, randomized trials, and systematic 
reviews of observational studies and short randomized trials.  Data from completed large scale 
randomized trials is currently unavailable. No data from unpublished literature or studies 
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unavailable in English were included so this review has a potential for publication and language 
bias.  
Conclusions: The harms of low dose CT screening for lung cancer are poorly reported in 
screening trials.  Even though harms are incompletely characterized in the included studies, 
these harms are likely clinically significant.  Clinicians must weigh the risks and benefits of the 
screening procedure if they are to implement mass screening for lung cancer with LDCT.  
Introduction: 
Background 
To date, lung cancer screening has not proven useful.   Systematic reviews have not 
shown a mortality benefit to screening for lung cancer1-4.  No current guidelines recommend 
mass screening for lung cancer, and the American College of Chest Physicians recommends 
that individuals at high risk should only undergo screening as part of a clinical trial5,6.  However, 
preliminary data from the NLST randomized screening trial show a 20% reduction in mortality 
for those who received a LDCT screening exam compared to the control group7.  While this data 
is encouraging in the fight against lung cancer, a good quality screening program requires that 
the benefits outweigh the harms.  No current systematic review has been designed to fully 
characterize the harms of lung cancer screening with LDCT.  In order for clinicians, policy 
makers, and patients to make informed decisions about screening, a systematic review of 
screening harms is required.  This evidence will help clinicians, policy makers, and patients 
balance the benefits and risks of screening in a population at risk for lung cancer.  Due to the 
absence of a current systematic review, I will attempt to evaluate the harms of LDCT screening 
for lung cancer in this review.   
Burden of suffering 
Lung cancer is the leading cause of overall cancer death in the United States and 
worldwide8-10.  According to the American Cancer Society (ACS), lung cancer is expected to 
cause 157,300 deaths in 2010 in the US, representing approximately 28% of cancer deaths8.  In 
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2007, the most recent year for complete data available from the Centers for Disease Control 
(CDC), lung cancer was responsible for 6.5% of all US deaths11.  In 2010, the ACS predicted 
222,520 new cases of lung cancer will be diagnosed in the United States, 15% of all cancer 
diagnoses8.  In perspective, lung cancer causes more deaths per year than stroke (136,000), 
lower respiratory disease (128,000), and accidents (124,000)12.  If lung cancer mortality was an 
individual category, it would be the third leading cause of death in the US, behind only heart 
disease and all other cancers.  
Worldwide, the ACS and the International Agency for Research on Cancer (IARC) 
estimated about 1.6 million new cases were diagnosed in 2008, representing about 13% of all 
cancer diagnoses9,10.  Deaths from lung cancer totaled 1.4 million in 2008, representing 18% of 
all cancer deaths9,10.  Lung cancer is the leading cause of cancer death in males, and is second 
in females behind only breast cancer9,10.   
Lung cancer incidence in males has decreased in the United States over the past 
decade, but has increased among females from 1991 to 200613,14.  During the same period in 
the US, mortality rates have decreased among males but have increased and remained stable 
since 2003 for females13,14.  Even though rates among males have decreased, absolute 
incidence and mortality remain higher for males compared to females.  Tobacco use patterns 
are likely contributing to the divergent trend observed between sexes.  As a result, prevention 
strategies to decrease lung cancer incidence and mortality among both groups remain a priority.  
Prevention Strategies 
The primary risk factor for developing lung cancer is tobacco use15.  In 2000, tobacco 
use was responsible for 435,000 deaths in the United States16.  This represents 18.1% of all US 
deaths in that year.  These deaths include not only lung cancer, but other cancers, respiratory 
illnesses, and cardiovascular diseases associated with tobacco use.  According to the CDC and 
a 2004 report from the Surgeon General, tobacco use is attributable to 80-90% of lung cancer 
deaths in the US15,17.  Male smokers are 23 times as likely to develop lung cancer as 
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nonsmoking males over their lifetime15.  Female smokers are 13 times as likely to develop lung 
cancer as nonsmoking females over their lifetime15.   Former male smokers are 9 times as likely 
to develop lung cancer as never smokers15.  Former female smokers are 5 times as likely to 
develop lung cancer as female never smokers15.  After 20 years of tobacco cessation, lung 
cancer risk decreases to about 2 times that of never smokers but never reaches the risk of a 
never smoker18.  Lung cancer risk from tobacco exposure is dose dependent, so the more one 
smokes, the greater the risk of developing cancer19.  While other risk factors play a role in 
developing lung cancer, this demonstrates that the main priority for prevention of lung cancer 
deaths is tobacco cessation and use prevention.  
As tobacco use contributes the majority of risk for developing lung cancer17, prevention 
of lung cancer is straightforward.  Smoking cessation and use prevention is the priority.  While 
the prevalence of smoking in the US has decreased since the 1980s according to data from the 
National Health Interview Survey, 20.6% of adults, or 46.6 million people, were current smokers 
in 200920.  An estimated 23.5% of men and 17.9% of women were current smokers in 2009 and 
an additional 21.9% of the population was considered a former smoker20.  This shows that 
42.5% of the US population was either a current or former smoker in 2009, which demonstrates 
the significant proportion of individuals at increased risk for developing lung cancer compared to 
never smokers.  While prevention of tobacco use is a priority, individuals remain at risk for lung 
cancer long after they quit smoking as cancer takes many years to develop.  Thus, lung cancer 
screening has been proposed as a tool to reduce the burden of suffering.  
In addition to primary prevention, screening for early disease has been proposed to 
combat lung cancer mortality.  While the greatest reduction in the burden of suffering would 
likely come from a reduction in smoking rates, early detection could further reduce the burden of 
suffering if screening randomized controlled studies demonstrate a reduction in lung cancer 
mortality.  
History of Screening/Screening Methodology 
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Screening has the potential to detect early stage cancers which are more amenable to 
cure than late stage cancers.  Most lung cancers present with symptoms and are diagnosed in 
an advanced stage when prognosis is poor21.  Only 15% of lung cancers were diagnosed in a 
local stage in 200613.  The ideal screening test would decrease mortality by improving the 
probability of cure from early detection of early stage cancers.  To date, a mortality benefit for 
lung cancer screening has not been shown.  Even if a mortality benefit is eventually shown, 
screening for early stage cancers can only be effective if the benefits outweigh the harms.  
Burden of testing, incidental findings, cost, workup morbidity and mortality, anxiety, surgical 
morbidity, radiation exposure, and screening biases need to be taken into account when 
weighing the risks and benefits of screening2,22.  However, because the prognosis of late stage 
cancers is dismal, even a small benefit in discovering and treating early stage cancers is likely 
to afford a mortality advantage.  As a result of this poor life expectancy, screening has been 
proposed as a possible mechanism to decrease lung cancer mortality. 
Lung cancer screening dates back to the 1960s when researchers studied chest x-ray 
and sputum cytology as screening modalities.  Early trials published in the 1960s and 1970s 
that evaluated chest x-ray and sputum cytology showed no mortality differences for the 
intervention group versus controls23-29.  Observational and experimental studies evaluating chest 
x-ray published in the 1980s and 1990s also failed to demonstrate a mortality benefit30-33.  
These studies were criticized for lack of adjustment for screening biases, study design problems 
including lack of power to detect mortality differences, and contamination in control groups34.  
Due to these problems, one arm of the current Prostate Lung Colon Ovarian (PLCO) Cancer 
screening randomized trial is designed to address mortality differences by comparing annual 
chest x-ray with usual care for early detection of lung cancer34.  This study sought to enroll 
158,000 individuals aged 55-74 years old with randomization into screening and usual care 
groups.  The lung cancer intervention arm offers smokers annual chest x-ray for 3 years and 
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non-smokers two annual repeat scans34.  Final results of this trial are currently unavailable, but 
are expected soon in 2012.  
Two up to date systematic reviews have explored the efficacy of lung cancer screening 
with chest x-ray for a reduction in mortality.  Seven controlled trials comparing chest x-ray with 
usual care were included in a Cochrane systematic review, six were randomized and one was 
non-randomized1.  This review reported a pooled analysis of no mortality benefit and suggested 
a possible mortality increase in the screening group.  A second systematic review also found no 
mortality benefit from screening with chest x-ray compared to controls2.  Together these reviews 
and the chest x-ray screening arm of the PLCO trial will likely address the issue of the efficacy 
of lung cancer screening with chest x-ray.   
Low dose CT screening for lung cancer was proposed in a 1990 study by Naidich et al35 
who compared the feasibility of conventional CT versus low dose CT of the chest.  
Observational studies evaluating low dose CT screening for lung cancer followed soon 
thereafter.  LDCT screening has been shown to detect early stage lung cancers in uncontrolled 
observational studies36-46.  Observational studies and short randomized trials of LDCT have 
been evaluated in systematic reviews which have demonstrated no mortality benefit to 
screening2-4,47.  Due to the screening biases of length time, lead time, and overdiagnosis bias 
inherent in observational studies, it is difficult to discern whether any observed survival 
differences are due to actual reductions in mortality from screening or due to bias22.  Studies 
without a control group may overestimate survival and only a randomized controlled trial 
comparing screening with LDCT to a control group can validly evaluate any mortality 
difference22.  However, published data from completed randomized controlled trials are not yet 
available.   
The NLST study comparing LDCT screening versus chest x-ray in a population with at 
least 30 pack-year history smokers will be published soon in 201148,49.  The NELSON trial from 
the Netherlands and Belgium is evaluating LDCT versus usual care in a high risk population and 
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will be published soon thereafter in 201250.  These trials will address the question of whether or 
not there is a mortality benefit to LDCT screening for lung cancer.  However, the goal of this 
review is to evaluate the harms of LDCT screening.  As the characterization of harms likely does 
not suffer from the same screening biases as mortality evidence, this review will include 
observational studies, randomized trials, and systematic reviews when available.  
Summary 
The best method to decrease mortality from lung cancer is to prevent it from occurring in 
the first place.  As mentioned, the majority of risk of developing lung cancer is attributed to 
smoking.  Thus, tobacco cessation programs and use prevention have the greatest likelihood of 
decreasing lung cancer mortality.  But for those who already have a smoking history or are at 
greater risk for lung cancer, an intervention that decreases lung cancer mortality may benefit the 
high risk population.  Researchers are evaluating LDCT screening as a viable option.  
Studies have evaluated individual harms of LDCT screening for lung cancer, but have 
not fully addressed all harms including, but not limited to, burden of testing, invasive 
procedures, anxiety, false positives, radiation exposure, and incidental findings.  This review will 
attempt to characterize the harms of screening for lung cancer with LDCT.  This will help 
clinicians, policy makers, and patients weigh the risks and benefits of screening in order to 
make informed decisions.   
This review will attempt to answer the following key questions: 
Key Questions 
(1) What is the evidence for harms associated with LDCT screening? (burden of testing, 
incidental findings, false positives, false negatives, testing burden, adverse effects of 
treatment, radiation exposure)  
(1a) What is the evidence for  potential biases in screening for lung cancer? 
(length time, lead time, overdiagnosis) 
(2) Are these harms able to be quantified? 
 
 
9 
 
Methods: 
As published evidence thus far has shown no mortality benefit, I focused this review on 
the harms of screening.  To address the focused question of identifying and quantifying the 
harms in lung cancer screening, a brief search of systematic reviews was conducted to 
determine if a review was indicated.  No systematic review has been published that addresses 
potential harms of lung cancer screening with LDCT. 
Data Sources and Searches 
I searched the MEDLINE, EMBASE, and CENTRAL online databases from inception to 
6/1/2011 to identify relevant articles.  I used the MeSH terms of “lung neoplasm,” “mass 
screening”, "tomography, x-ray computed," and “tomography, spiral computed” plus keyword 
searches of low dose CT and screening harms.  Complete search terms are provided in the 
appendix.  I also hand searched relevant reviews and reference lists of included studies for 
articles.  An attempt to locate gray literature was made in a search of clinicaltrials.gov for trials 
currently underway and in consultation with experts.  An experienced research librarian was 
consulted in formulating the search strategy.  
Study Selection 
This review will include original research papers that are relevant to answer the key 
questions of screening harms.  One author reviewed the initial full set of identified titles and 
abstracts.  If it was not clear from the title or abstract if the study fit inclusion criteria, it was 
included for full text review to maintain a sensitive search.  If multiple articles were published on 
one study, all relevant data was abstracted for our outcomes of interest.  Reference lists of 
included studies were searched for relevant articles.  
I included systematic reviews, randomized controlled trials, non-randomized trials, and 
prospective cohort studies.   Cohort studies were included because it is likely that harm data are 
not subject to lead or length time bias as compared to that of mortality data, however there are 
other biases that needed to be taken into account.  Systematic reviews were included for 
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identification of primary studies and were not included in the analysis.  If systematic reviews 
quantified harms, I commented on these in the discussion section of this paper.  We included 
any population of current or former smokers who have received a low dose CT scan for the 
purpose of screening for lung cancer.  Studies were eligible for any duration of follow up as 
potential screening harms can be immediate, such as false positives or anxiety of awaiting 
results.  Studies conducted in any setting that has the potential for lung cancer screening were 
eligible, including primary care and specialty settings.  I required the study to measure at least 
one of the primary outcomes harm as described in the PICOTS in Table 1.  Excluded articles 
included editorials, non-systematic reviews, case reports, and case series.  Studies were 
excluded if they did not evaluate low dose CT as the intervention screening modality, such as 
those that evaluated chest x-ray or sputum cytology.   
Data Extraction and Quality Assessment 
I collected data from the included studies into evidence tables using a standard data 
collection form.  Information collected included study design, population, intervention, 
comparators, and outcome measures as described in Table 1.  Studies reporting incomplete 
outcomes were reported in the analysis.  No attempt was made to contact the primary authors 
to obtain data. I assessed quality using the USPSTF methodology51.  One author completed 
quality assessment for each study.   
Data Synthesis and Analysis 
I reported data for each of our primary outcomes if available in the included studies.  A 
qualitative synthesis was conducted for each of the primary outcomes of interest due to the 
heterogeneity of study populations.  Heterogeneity was not formally assessed using statistical 
methods due to the variability of eligibility criteria and differences in study protocols across the 
included studies.  I used the PRISMA reporting guidelines for systematic reviews to preserve 
completeness52,53.  
 
 
 
11 
 
PICOTS: 
 
Category Inclusion criteria 
Population Current and former tobacco smokers, including groups identified in the 
literature as high risk, low risk, and those whose risk is not defined, no 
restriction on numbers of pack-years 
- Former users as defined in literature 
Intervention Screening with low dose CT scan, any interval 
Comparators Usual care, chest x-ray, sputum cytology, different combinations of 
these 
Outcomes Primary outcomes: 
- Harms of screening/workup 
- Testing burden 
- Invasive procedures (including biopsies, thoracotomies, VATS) 
- False positives 
- False negatives 
- Radiation exposure 
- Incidental findings 
- Anxiety 
- Unnecessary procedures 
- Repeat imaging – especially associated with radiation exposure, 
HRCT, PET 
- Overdiagnosis 
- Quality of life 
 
Secondary outcomes: 
- Smoking cessation rates of abnormal result 
Timing of effect Harms: any time period 
Timing of search Since MEDLINE inception – 1966 to present 
Setting Primary care, specialty care, inpatient setting, or other relevant lung 
cancer screening settings 
Study Design SRs, RCTs, non-randomized trials, prospective cohort studies 
Table 1. Defining PICOTS framework for systematic review of lung cancer screening harms. 
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Results: 
A total of 655 titles and abstracts were identified and reviewed using our search strategy.  
Of these, 215 were included for full text review.  Articles were excluded for wrong interventions, 
poor outcome reporting, duplicate publications, wrong design, poor quality, and inability to 
obtain an English translation, special populations.  Nine articles were reviewed from searching 
reference lists.  On final inclusion, 46 articles from 20 studies were included in this review.  Six 
randomized controlled trials and 14 cohort studies were included.  Eight systematic reviews and 
ten articles from special populations (asbestos, nuclear plants) were identified.  Most 
randomized trials only reported baseline findings.  A flow diagram of the results of our search 
strategy is shown in Figure 1. 
Summary of Study Descriptions 
Characteristics of included studies are summarized in Table 2.  A total of 94,521 low 
dose CT screening exams were performed for 46,946 participants in the included studies.  
Median age ranged from 53 to 67 years old.  Median smoking history ranged from 30 to 54 
pack-years.  Low dose CT slice thickness ranged from 0.75 to 11 mm.   
The total number of lung cancers diagnosed was 845 with 67% of these diagnosed at baseline 
screening.  Baseline positivity ranged from 5 to 53%.  Stage I disease was diagnosed in 38 to 
93% of lung cancers with 17 to 85% of all cancers representing adenocarcinomas.  Lung cancer 
outcomes are summarized in Table 3.  Study descriptions and lung cancer outcomes are 
provided in text form in the appendix.  
Quality Summary of Included Studies 
Quality assessment is summarized in Table 4.  One study was rated as good and the 
remaining demonstrated fair quality.  Main issues were poor adherence and limited description 
of recruiting strategies which has the potential to introduce selection bias.  Most studies did not 
provide details about masking of the intervention to the investigator or participant.  Masking 
would likely be unfeasible in subjects in randomized trials as they likely know if they are 
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undergoing a CT scan versus a chest x-ray or usual care.  Generalizability was difficult to 
determine due to inadequate description of recruiting strategies inhibiting the ability to determine 
the source population.  A final issue included poor reporting of target outcomes, especially for 
incident scans.  Complete quality assessments for individual studies are reported in the 
appendix.  
Summary of Target Outcomes 
Total positivity of low dose CT screening ranged from 8 to 45%.  For the studies 
reporting workup, 5 to 28% of those screened at baseline received some further workup as a 
result of a screening test.  A range of 4 to 55% of total invasive procedures were performed for 
benign lesions.  None to 40% of surgical procedures were performed for benign lesions.  In the 
studies that reported incidental findings, 0.77 to 62% of those screened had abnormal findings 
other than lung nodules.  Studies reported on extra-pulmonary tumors, emphysema, 
bronchiectasis, lymphadenopathy, aneurysms, coronary calcifications, renal abnormalities, and 
adrenal abnormalities.  30% of the included studies mentioned anxiety or burden of testing and 
55% of included studies mentioned overdiagnosis as potential harms to lung cancer screening.  
Half of the studies reported observed morbidity and mortality for diagnosis or treatment.  35% of 
studies reported false negative cases.  The false positive rate of baseline LDCT ranged from 86 
to 98%.  Target outcomes for studies are summarized in Table 5 and are individually addressed 
in the text below.  
Depiscan - Blanchon54  
Total positivity rate was 45%.  I could not determine who received further workup after 
screening exams.  The study reported 12 total invasive procedures with 25% for benign lesions, 
however it was unclear if participants received more procedures than were reported.  38% of 
surgeries were performed for benign lesions.  Incidental findings were briefly reported and 
included a 6% rate of severe emphysema, 19% with bronchiectasis, and 5% with mediastinal 
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abnormalities.  No morbidity or mortality was reported in the LDCT screening group.  No false 
negative cases were reported. The false positive rate of LDCT was 95% at baseline. 
Colorado - Garg55 
Total positivity rate was 33%.  28% of LDCT screened participants received further 
workup.  Invasive procedures and surgeries were not reported.  Incidental findings were not 
reported, but one case of metastatic laryngeal cancer was mentioned.  Morbidity, mortality, and 
overdiagnosis were not mentioned as potential harms.  No false negative cases were reported.  
The false positive rate was 90%. 
DANTE - Infante56-58 
Total positivity rate was 28% for baseline and incident screens combined.  18% of those 
screened received some form of further workup.  Of those who screened positive, 57% received 
a high resolution CT and 16% received a PET scan.  Ninety-six invasive procedures were 
performed, 11% were for benign lesions.  13% of thoracotomies were performed for benign 
lesions.  Five of the 46 total thoracotomies were required for non-lung cancer lesions including 
mesothelioma, esophageal cancer, complex aspergilloma, empyema, and leiomyoma.  
Incidental findings were reported in 3% of subjects.  These included effusions, pleural lesions, 
mediastinal masses, hiatal hernias, aortic aneurysms, goiters, renal and adrenal masses, and 
diaphragmatic paralysis.  Two post-operative deaths were reported.  Overdiagnosis was 
mentioned as a potential harm of screening.  One false negative case was detected on sputum 
cytology. The false positive rate was 86% at baseline.  
ELCAP - Henschke36,37 
Total positivity rate was 26% for baseline and incident screens combined.  18% of those 
at baseline and 3% of those who received a repeat screen received some form of further 
workup.  All participants who received further workup received additional diagnostic imaging.  
Forty invasive procedures were performed, 13% were for benign lesions.  Of note, 3 of these 
were against study protocol.  It was unclear how many surgical procedures were performed but 
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no thoracotomies were performed for benign lesions.  Incidental findings were not reported in 
the primary articles.  Morbidity, mortality, and other potential harms of screening were not 
reported.  Five false negative cases were reported as four lung cancers and one interim cancer 
were visible on baseline exam.  The false positive rate was 88%.  
 A follow study conducted by Anderson et al examined whether negative screening 
results influenced smoking cessation behaviors on a subpopulation of those in the ELCAP 
study59.  The study found that negative scans were not associated with a lower likelihood of 
prolonged abstinence among baseline smokers or a higher likelihood of relapse among former 
smokers over 6 years of follow up compared with those with a false positive result.  In other 
words, negative scans were not associated with adverse smoking behavioral changes.  
However, smoking status was not collected uniformly throughout the study period and could 
influence measurement of results.  In addition, 39% of those who reported quitting during the 
study period were excluded from analysis because of missing data.   
 A second follow up study evaluated smoking behaviors among a subpopulation of 313 
individuals from the ELCAP sample60.  Cancer anxiety and perceived health benefits of quitting 
were found to be predictors of smoking cessation following LDCT exam.  However, the result of 
the screening exam, whether positive or negative, was not statistically significantly associated 
with smoking cessation.   
NY-ELCAP61  
Total positivity was 10% for baseline and incident screens combined.  8% of those at 
baseline and 3% of those who received a repeat screen received further workup.  I could not 
determine who received additional diagnostic imaging.  A total of158 biopsies were performed 
but 134 were performed as recommended by the study protocol.  Of all biopsies, 21% were 
performed for benign lesions.  Of the recommended biopsies, 7% were performed for benign 
lesions.  The study reported no lobectomies were performed for benign lesions however it is 
unclear if any thoracotomies or VATS were performed for biopsy or benign lesions.  No post-
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operative deaths of workup or treatment were observed.  No complications were mentioned.  
Incidental findings were not reported in the primary article, however the study reported four 
cancers detected on biopsy that were not lung cancer, including 2 cases of metastatic colorectal 
cancer and 2 cases of lymphoma.  The study mentions overdiagnosis as a potential harm to 
lung cancer screening.  The study did not report any false negative cases.  The false positive 
rate of LDCT screening was 89% in this study.   
 A companion paper analyzed the frequency of mediastinal masses detected in both the 
ELCAP and NY-ELCAP populations62.  The authors reported a prevalence of 0.77% of those 
screened who had any mediastinal mass.  These included masses in the thymus, thyroid, 
esophagus, and trachea.  Other incidental findings were noted but not reported in this paper.  
Matsumoto - Sone43,63,64  
Total positivity rate was 4.3% for baseline and incident screens combined.  4.9% of 
those at baseline, 3.8% of those screened at first repeat, and 3.3% of those screened at second 
repeat received further workup.  I could not determine who received further diagnostic imaging.  
Seventy-two invasive procedures were reported, all were surgical biopsies.  22% of these 
surgeries were performed for non-cancerous lesions.  Incidental findings were not reported.  
The study reported 24 false negative cases.  No complications were mentioned.  The false 
positive rate was 92%.   
 A follow article reported 10 year follow up of the study cohort64.  Main outcomes in this 
article included survival of patients diagnosed with CT detected lung cancer.  However, the 
study did include an estimated overdiagnosis rate of 13% using a formula which included the 
volume doubling time of the tumor and the patient‟s age.   
ALCA – Sobue/Kaneko42,65 
Total positivity rate was 9.5% for baseline and incident screens combined.  12% of those 
at baseline and 9.8% of those screened at repeat screening received further workup.  97% and 
99.7% of positives at baseline and repeat screening, respectively received additional diagnostic 
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imaging.  Seventy-one total invasive procedures were performed, 49% were for benign lesions.  
Twenty-one total surgeries were performed with a 29% rate for benign disease.  Incidental 
findings were not reported in the primary articles.  Two deaths from post-surgical infection were 
recorded.  There were no adverse events of biopsy observed.  Anxiety and overdiagnosis were 
mentioned as potential harms to screening.  No false negatives were reported.  The false 
positive rate was 95%.  
ITALUNG – Lopes Pegna66 
Total positivity rate was 30%.  26% of LDCT screened participants received further 
workup.  Fifty-two invasive procedures were performed, 4% were for benign lesions.  One of the 
18 surgeries performed was for a benign lesion, a rate of 5.5%.  Incidental findings were not 
reported.  Morbidity, mortality, and overdiagnosis were not mentioned as potential harms.  No 
false negative cases were reported.  The false positive rate was 95%. 
COSMOS - Veronesi67-69 
Total positivity rate was 53% for baseline screening and could not be determined for 
incident screening.  9.7% of those screened received further workup including diagnostic testing 
and biopsy.  This study reported 104 surgeries with 14% of those for benign lesions.  
Procedures included 5 VATS wedge resections, 9 open wedge resections, and 1 open 
lobectomy.  This study did not report incidental findings. The study mentions radiation exposure 
and overdiagnosis as potential harms to LDCT screening for lung cancer.  Major post-operative 
morbidity was reported in 4.6% of cancer resections.  No peri-operative morbidity occurred in 
surgeries for benign disease and no post-operative mortality was observed among surgeries.  
The study reported 24 false negative cancers that had a prevalent lesion on baseline.  The false 
positive rate was 98% at baseline. 
Munster - Diederich39,40,70 
Total positivity rate was 18% for baseline and repeat screening combined.  I could not 
determine who received further workup after a positive result.  The study reported 20% of the 16 
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invasive procedures performed at baseline were for benign lesions.  Three surgical procedures 
were performed at baseline, but I could not determine the proportion of total surgeries that were 
performed.  This study did not report incidental findings but reported on seven cases of lung 
metastases from unknown primary malignancies.  Overdiagnosis was mentioned as a potential 
harm to screening for lung cancer.  One post-operative death was observed following 
bilobectomy for cancer treatment.  Four false negative cases were reported as abnormal 
baseline scans but were diagnosed symptomatically within screening intervals.  The false 
positive rate on baseline scan was 96%. 
Hitachi - Nawa41 
Total positivity rate was not reported and I could not determine who received further 
workup.  At baseline, 6.8% received diagnostic CT whereas 2.7% received diagnostic CT at 
repeat screening.  Seventy-one invasive procedures were performed in total, but it was not clear 
how many were for benign lesions. Seventeen of 57 surgeries, or 30%, were performed for a 
benign lesion.  The authors reported extrapulmonary tumors as incidental findings.  These were 
tumors in the thyroid, parathyroid, mediastinum, and chest wall.  No complications of workup 
were reported.  The false positive rate at baseline was 98%. 
Milan - Pastorino71 
Total positivity rate was 15% for baseline and repeat screening combined.  I could not 
determine who received further workup.  6% of those screened at baseline and 3.4% of those 
screened at repeat screening had further diagnostic imaging performed.  Total invasive 
procedures were not reported.  22% of the 27 total surgeries were performed for benign lesions.  
Incidental findings were not reported.  No post-operative deaths were observed during study 
follow up.  The authors mention anxiety and overdiagnosis as potential harms to lung cancer 
screening.  No false negative exams were reported.  The false positive rate was 94% at 
baseline.  The authors reported an average effective radiation dose of 0.7 mSv per screening 
exam.  
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Mayo Clinic - Swensen44,45,72,73 
Total positivity rate was 51% for baseline screening and 74% of those screened had at 
least one non-calcified nodule (NCN) detected on any screen over the 5 total screening exams.  
I could not determine who received further diagnostic imaging or invasive diagnostic 
procedures.  At 3 year follow up, 8 of 39 surgeries were performed for benign lesions, a rate of 
21%.  At 5 year follow up, 15 surgeries were performed for benign lesions out of an unknown 
total.  This study reported that 79% of those screened had either a pulmonary lesion or an 
incidental finding after 3 years of follow up.  The most common extra-pulmonary findings 
included lymphadenopathy, aortic aneurysms, renal abnormalities, and adrenal abnormalities.  
In addition, 18 extra-pulmonary tumors were detected including cases of renal cell carcinoma, 
breast cancer, lymphoma, carcinoid, ovarian cancer, pheochromocytoma, and metastases. The 
study mentions both anxiety of workup and overdiagnosis as potential harms to LDCT screening 
for lung cancer.  The study reported 5 false negative cases, 1 sputum detected case that was 
visible on baseline scan and 4 cancers detected on incident scans that were visible on prior 
scans.  The false positive rate was 96% at baseline. 
 A follow up article by Cox et al reported on smoking changes of 97% of the Mayo study 
participants with smoking data at baseline74.  14% of baseline smokers quit at one year and 
10% former smokers were smoking at one year.  A longer duration of cessation was associated 
with abstinence at one year for former smokers.  A positive screening result was not associated 
with cessation and a negative screening result was not associated with continued smoking or 
relapse.  The study was not designed to determine if screening was associated with any change 
as there was no non-screened control group.   
A second follow up article by Townsend et al evaluated the relationship between 
smoking cessation and results of screening exam over three annual screening exams75.  This 
study included 91% of the original Mayo cohort with 926 current smokers and 594 former 
smokers.  Smoking cessation after baseline exam was associated with older age, worse 
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baseline lung function, and abnormal CT findings on prior screening exam.  For those who 
received 3 abnormal exams, 42% reported quitting smoking.  For those who received 2 
abnormal exams, 28% reported quitting.  For those with one abnormal exam, 24% quit.  For 
those without an abnormal exam, 20% quit.  It appears this association is dose dependent.  
Longer duration of abstinence was the only predictor of maintaining abstinence among former 
smokers.   
 Another follow up study by Crestanello et al more closely examined thoracic surgery 
procedures in the Mayo cohort through 200273.  The article reported a total of 60 surgical 
procedures in 55 patients performed for diagnosis and treatment.  Lobectomy was the most 
common procedure followed by wedge resection.  Ten surgeries were performed for benign 
disease, a rate of 18.1%.  One lobectomy and nine limited resections were performed for benign 
lesions.  Complications occurred in 27% of surgeries including air leak, arrhythmia, pneumonia, 
ileus, stroke, depression, vocal cord paralysis.  One death (1.7%) occurred post-operatively 
from an intracerebral hemorrhage.  A total of 79 nodules were resected, 39% of these nodules 
had benign pathology.  
PLuSS - Wilson76,77 
Total positivity rate was 41% for baseline and incident screens combined.  22% of those 
screened at baseline had further diagnostic imaging, or 56% of those that screened positive.  
Total invasive procedures were not reported, but 90 total surgeries were performed.  40% of 
these were for non-cancerous diagnoses.  82 surgeries were performed for lung cancer 
suspicion and 28 of these were for benign lung lesions, a rate of 34%.  The remaining 8 
surgeries were performed for suspicious incidental findings ultimately diagnosed as benign 
lesions.  Incidental findings were not well reported however 9 extra-pulmonary malignancies 
were discovered including 4 cases of lymphoma and 5 metastatic lesions in the lung.  Morbidity 
and mortality of workup and overdiagnosis were mentioned as harms to screening but were not 
quantified. The false positive rate at baseline was 96%.  
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 A companion paper explored healthcare usage after LDCT screening in a subpopulation 
of 400 participants in the PLuSS cohort78.  There were no observed differences between 
groups, however data showed an increase in outpatient visits over the first 6 months following 
the screening exam, regardless of whether the participant received a positive or negative result.  
Visits declined to pre-screening levels over the next 6 months.  These data show that a 
temporary increase in visits occurred following screening, but this increase was not sustained 
past 6 months.   
 A follow article presented results exploring the relationship of emphysema diagnosed on 
CT with airflow obstruction76.  This paper found that 24% of those screened had mild to 
moderate/severe emphysema on LDCT.  It is unclear if these results are clinically significant, 
however emphysema was found to be independently associated with lung cancer.   
PALCAD - MacRedmond79,80 
Total positivity rate was 25% for baseline and incident screens combined.  I could not 
determine who received further workup or the total number of invasive procedures performed.  
Five invasive procedures were performed for benign lesions. One of 4 surgeries was performed 
for a benign lesion.  Incidental findings were well reported.  62% had any incidental finding on 
baseline screen with 49% having a clinically significant finding requiring further workup.  Most 
common findings included emphysema (29%), coronary calcification (14%), bronchiectasis 
(10%), and abdominal abnormalities (10%).  One complication of workup was reported as a 
pneumothorax for a FNA biopsy.  The false positive rate at baseline was 98%.  
LSS – Gohagan81,82 
Total positivity rate was 23%.  19% and 24% of those screened at baseline and repeat 
screening received any further workup, respectively.  73% and 40% of positive results at 
baseline and repeat screening received further diagnostic imaging, respectively.  There were 
107 invasive procedures performed in total.  At baseline, 23 people received an invasive 
procedure for a benign lesion, 43% of all procedures.  Forty-six biopsies and resections were 
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performed at baseline, 39% of these for a benign diagnosis.  Eighteen biopsies and resections 
were performed after repeat screening and it was unclear how many of these were for benign 
lesions.  Ten participants had complications related to follow up including pneumothorax, 
infection, stroke, respiratory failure, and pneumonia.  The study mentioned anxiety and 
overdiagnosis as potential harms to lung cancer screening.  Incidental findings were not 
reported in the primary articles, however a follow up letter reported proportions of incidental 
findings described below.  No false negative cases were reported. The false positive rate at 
baseline was 91%.  
 Incidental findings of the Lung Screening Study were reported in a letter by Pinsky et 
al83.  Of those who received a LDCT screening exam, 16% had a nodule or mass, 17% had a 
granuloma, 29% had scarring or fibrosis, 25% had COPD, 10% had pleural fibrosis, 0.32% had 
pleural fluid, 1.5% had a bone or soft tissue abnormality, 14% had a cardiac abnormality, and 
19% had coronary artery calcifications.  It is unclear if these incidental findings were clinically 
significant.  
 A follow up study by Croswell et al examined the cumulative risk for false positive 
screening exams84.  This study defined a false positive result as a positive LDCT screen with 
negative workup or one year without a lung cancer diagnosis. The primary outcome showed that 
the cumulative probability of obtaining a false positive screening test was 33% (CI: 31, 35%) 
after two LDCT screening exams in this population.   
Toronto – Menezes85 
Total positivity rate was 10% for baseline and incident screens combined.  It appeared 
that 100% of those who screened positive had further workup consisting of LDCT, diagnostic 
CT, and/or biopsy.  A total of 78 biopsies were performed with 16 resulting in a non-cancer 
diagnosis, a rate of 21%.  It was unclear how many surgeries were performed and if any 
surgeries resulted in benign lesions.  The authors did not report on incidental findings.  The 
authors mention overdiagnosis as a harm of LDCT screening for lung cancer.  There was one 
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pneumothorax recorded as a complication of a biopsy.  The false positive rate at baseline was 
91%. 
Israel - Shaham86  
Total positivity rate was 8.2% for baseline and incident screens combined.  I could not 
determine who received further workup.  There were 16 reported invasive procedures 
performed, all were biopsies of lung lesions.  Two of the 12 total surgeries were performed for a 
benign lesion for a benign surgical rate of 17%.  Of note, these surgeries were against 
recommended protocol.  Incidental findings were not reported.  The study did not report 
complications of workup or resection.  The false positive rate at baseline was 88%. 
DLCST – Pedersen87  
Total positivity rate was 8.7% as only baseline results have been reported.   I could not 
determine who received further medical evaluation after screening.  There were 40 total 
invasive procedures performed with 25% of invasive procedures performed for a benign lesion.  
Eleven surgeries were performed, 2 of these (18%) were performed for benign lesions.  
Incidental findings were not recorded.  One post-operative death was reported following 
lobectomy for adenocarcinoma, but no morbidity or mortality was reported for work up.  No false 
negative cases were reported. The false positive rate at baseline was 91%.  
 A companion article by Ashraf et al sought to determine smoking cessation changes in 
this trial88.  Primary measures were cessation and relapse rates at one year.  No statistically 
significant differences in cessation or relapse rates for LDCT versus control groups were 
observed.  However, those who received a positive screening result in the CT group had a 
higher quit rate than those in the CT group who did not have a positive result (17.7% vs 11.4%, 
p=0.04).  Similarly, those who had a positive screening result were less likely to relapse than 
those without a positive result in the CT group (4.7% vs 10.6%, p<0.01).  
 
 
 
 
24 
 
Toronto – Roberts89 
Total positivity rate was 26% for baseline screening.  The study states that 100% of 
those who screened positive had further workup, with 98% receiving further imaging.  A total of 
26 invasive procedures were performed for workup with 15% of these performed for benign 
lesions.  The authors reported 3 surgeries for workup of which none were performed for benign 
indications.  The majority of cancers were diagnosed with CT-guided biopsy.  The authors 
reported 6 incidental findings consisting of one abnormal pulmonary vein, one mediastinal cyst, 
one mild lymphadenopathy, one thickened diaphragm, one carcinoid tumor, and one 
plasmacytoma.  The authors mention overdiagnosis and anxiety as a harm of LDCT screening 
for lung cancer.  No complication or mortality was reported as a result of workup.  No false 
negatives were reported.  The false positive rate at baseline was 92%. 
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Figure 1. Flow diagram of search strategy. 
Title review led to 
exclusions: 
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Studies identified from 
reference lists 
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Full text retrieved and 
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interest reported n= 19 
*Wrong intervention 
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Publications meeting 
inclusion criteria n=119 
46 articles from 20 
studies included in 
review 
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reporting n= 31 
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*Duplicate publication 
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Author 
year 
starte
d 
# 
scree
ned 
with 
LDCT 
at 
baseli
ne  
total # 
LDCT  
screeni
ng 
tests 
perfor
med population 
fem
ales 
(%) 
age 
rang
e 
me
dia
n 
age 
(ye
ars) 
smoki
ng 
histor
y 
(medi
an p-
y) 
% 
current/fo
rmer/nev
er 
smokers 
LDCT 
slice 
thicknes
s (mm) 
Blancho
n 2002 336 336 
subjects were under 
care of GP 
recruiters, 
asymptomatic >15 
cigs/day for >20 yrs 
(quit <15 yrs prior) 29 
50-
75  56 30 64/36 1.5 
Diederic
h 1995 817 2542 
asymptomatic 
volunteers recruited 
by media, >20 p-y 
history 28 >40 53 45 - 5 
Garg 2001 92 92 
veterans, included 
those with COPD 
and sputum atypia 
in previous cohort or 
>30 p-y. recruited 
via telephone. 3 
50-
80 - - - 5 
Gohaga
n  2000 1586 2984 
volunteers recruited 
via mass mailing 
and referral, >30 p-y 
(quit w/in 10 yrs). 
From PLCO centers 
not already in PLCO 
trial 41 
55-
74 - 54 58/42 5 
Hensch
ke 1992 1000 2184 
asymptomatic 
volunteers recruited 
from physician 
offices and 
hospitals, >10 p-y 46 >60 67 45 - 10 
 
 
27 
 
Infante 2001 1276 3612 
male volunteers 
recruited via GPs 
and mass 
mailings/media, >20 
p-y (quit <10 yrs) 0 
60-
74 65 47 56/44 5 
Sobue/K
aneko 1993 1611 9502 
subjects from a 
dues paying 
organization that 
provides lung 
cancer screening to 
its members, 
includes never 
smokers.  12 
40-
79 - - 62/25/14 10 
Lopes 
Pegna   1406 1406 
recruited by sending 
invitation letters to 
registered patients 
of GPs, >20 p-y 
history 35 
55-
69 
61 
(me
an) 39 65/35 1-3 
MacRed
mond   449 1371 
recruited by media, 
residents of 
community served 
by hospital, >10 p-y 
smoking at 45 yo 50 >50 56 45 68/32 10 
Meneze
s 2003 3352 6924 
volunteers or 
referred by 
physician, >10 p-y 54 >50 60 30 NR 1-1.25 
Nawa 1998 7956 13524 
Hitachi employees, 
includes never 
smokers 21 
50-
69 - - 
62% 
current/fo
rmer, 
38% 
never 
smoker 10 
Pastorin
o 2000 1035 2031 
asymptomatic 
volunteers recruited 
via media, >20 p-y 29 >50 58 40 86/14 10 
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Pederse
n 2004 2047 2047 
volunteers recruited 
via media, >20 p-y 45 
50-
70 - - 76/24 0.75 
Roberts 2003 1000 1000 
volunteers, >10 p-y 
history 55 >55 63 34 34/66 1.25 
Shaham 1998 842 1784 
mixed referral from 
physician and 
volunteers from 
media, >10 p-y 43 >50 56 37 - 3.2 - 11 
Sone 1995 5483 13786 
volunteers recruited 
via media, includes 
never smokers 46 
40-
74 
64 
(me
an) - 
46% 
current 
/former.  
54% 
never 
smokers 10 
Swense
n 1999 1520 NR 
volunteers recruited 
via media, >20 p-y 48 >50 59 45 61/39 5 
Verones
i 2004 5201 10022 
asymptomatic 
volunteers from 
single center, >20 p-
y 34 >50 
58 
(me
an) 44 80/20 2.5 
Wilson 2002 3642 7065 
recruited volunteers 
from media, could 
include 
symptomatic, >12.5 
p-y history 49 
50-
79 
59 
(me
an) 47 60/40 2.5 
NY-
ELCAP 2000 6295 12309 
recruited via media 
and physician 
referral, >10 p-y 51 >60 66 40 33/67 1.25-10 
Table 2. Description of included studies. 
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Author 
year 
start
ed 
# 
scree
ning 
tests 
perfor
med 
# 
lung 
canc
ers 
total 
description of 
positive test 
# 
basel
ine 
positi
ve 
(%) 
basel
ine 
lung 
canc
ers 
detec
ted 
preval
ence 
repe
at 
posit
ive 
incid
ent 
lung 
canc
ers 
detec
ted 
% 
sta
ge 
I  
% 
adenocarc
inoma and 
BAC 
Blancho
n 2002 336 8 
any NCN 
without benign 
features 
152 
(45%
) 8 2.38% - - 
38
% 63% 
Diederic
h 1995 2552 29 
any NCN 
without benign 
features 
378 
(46%
) 12 1.35% 
89 
(13
%) 10 
56
% 41% 
Garg 2001 92 3 
1-6 NCN 
without benign 
features 
30 
(33%
) 3 3.26% - - - - 
Gohaga
n  2000 2984 40 
NCN >3 mm or 
other 
suspicious 
abnormalities 
325 
(21%
) 30 1.89% 
360 
(26
%) 8 
48
% 60% 
Hensch
ke 1992 2184 36 
1-6 NCN 
without benign 
features  
233 
(23%
) 27 2.70% 
30 
(2.5
%) 7 
82
% 68% 
Infante 2001 3612 63 
abnormality of 
malignancy 
including NCN 
>10 mm or 
smaller with 
suspicious 
features. 
Negative if 
NCN <5mm 
199 
(16%
) 28 2.19% 
152 
(4.2
%) 19 
65
% 43% 
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Kaneko/
Sobue 1993 9502 36 
those who 
were requested 
to undergo thin 
section CT 
scan based on 
suspicion of 
benign 
tumor/inflamma
tion/lung 
cancer  
186 
(12%
) 14 0.87% 
721 
(9.1
%) 22 
78
% 67% 
Lopes 
Pegna   1406 21 
at least 1 solid 
NCN >=5mm 
or nonsolid >= 
10mm or part 
solid NCN 
426 
(30%
) 21 1.42% - - 
48
% 48% 
MacRed
mond   1371 6 Any NCN   
105 
(23%
) 2 0.45% 
6 
(1.3
%) 3 
50
% 17% 
Meneze
s 2003 6924 65 
baseline: >1 
NCN >=5mm 
or non-solid >= 
8mm.  Repeat: 
growth or new 
NCN 
600 
(18%
) 56 1.67% 92 6 
65
% 68% 
Nawa 1998 13524 41 
Non-calc SPN 
>=8 mm 
without benign 
features 
2099 
(26%
) 37 0.45% - 4 
85
% 85% 
Pastorin
o 2000 2031 22 NCN >= 5 mm 
199 
(19%
) 11 1.06% 
99 
(10
%) 11 
77
% 77% 
Pederse
n 2004 2047 17 
NCN>=5mm 
and growing 
nodules 
179 
(8.7
%) - 0.83% - - 
53
% 71% 
Roberts 2003 1000 20 
>=1 solid/part 
solid NCN >=5 
mm or nonsolid 
>= 8 mm.  
256 
(26%
) 20 2% - - 
75
% 70% 
Shaham 1998 1784 14 
baseline: 1-6 
NCN >=5mm at 
first. Then 
adjusted to 1-6 
solid/part solid 
NCN >=5mm 
or >1 non solid 
>=8 mm. 
repeat: new 
and/or growth 
102 
(12%
) 12 1.43% 
45 
(5%) 2 
86
% 57% 
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Sone 1995 13786 60 
positive result 
included scan 
read as 
possible 
cancer, 
probable 
cancer, or 
small nodule 
<3 mm 
279 
(5.1
%) 22 0.40% 
309 
(3.7
%) 34 
88
% 85% 
Swense
n 1999 NR 68 any NCN 
780 
(51%
) 31 2.04% 
773 
(NR) 34 
57
% 53% 
Verones
i 2004 10022 92 any NCN 
2754 
(53%
) 55 1.06% 
45 
(0.9
%) 36 
66
% 68% 
Wilson 2002 7065 80 any NCN 
1477 
(41%
) 53 1.46% 42% 24 
50
% NR 
NY-
ELCAP 2000 12309 124 
baseline: at 
least 1 
solid/part solid 
NCN >= 5 mm 
or nonsolid 
NCN >= 8 mm. 
incident: any 
new NCN 
regardless of 
size or any 
growth.  
906 
(14%
) 101 1.60% 
361 
(6.0
%) 20 
93
% 60% 
Table 3. Results of included studies. 
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a
le
) 
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2
 re
a
d
e
rs
 in
d
e
p
e
n
d
e
n
tly
 re
a
d
 a
ll c
a
s
e
s
. D
is
c
re
p
a
n
c
ie
s
 re
s
o
lv
e
d
 a
t 
w
e
e
k
ly
 c
o
n
fe
re
n
c
e
s
. 
2
 ra
d
s
 in
d
e
p
e
n
d
e
n
tly
. D
is
c
re
p
a
n
c
ie
s
 re
s
o
lv
e
d
 b
y
 3
rd
 ra
d
. 
re
a
d
 b
y
 2
 ra
d
s
 (u
n
k
n
o
w
n
 in
d
e
p
e
n
d
e
n
c
e
). D
is
c
re
p
a
n
c
y
 b
y
 
c
o
n
s
e
n
s
u
s
. 
u
n
c
le
a
r w
h
o
/h
o
w
 m
a
n
y
 re
a
d
 s
c
a
n
s
 
c
h
a
n
g
e
d
 d
e
fin
itio
n
 o
f a
 p
o
s
itiv
e
 re
s
u
lt d
u
rin
g
 th
e
 tria
l, u
n
c
le
a
r w
h
e
n
. 
A
ls
o
 c
h
a
n
g
e
d
 s
lic
e
 th
ic
k
n
e
s
s
 w
h
ic
h
 w
o
u
ld
 a
ffe
c
t in
te
rp
re
ta
tio
n
 o
f 
im
a
g
e
s
.  O
n
e
 ra
d
io
lo
g
is
t re
a
d
 a
ll s
c
a
n
s
 
re
a
d
 b
y
 1
 o
f 4
 ra
d
io
lo
g
is
ts
, th
e
n
 2
n
d
 re
a
d
e
r re
a
d
 s
u
s
p
ic
io
u
s
 o
r 
c
lin
ic
a
lly
 s
ig
n
ific
a
n
t s
c
a
n
s
.  U
n
m
a
s
k
e
d
 to
 firs
t re
a
d
. 
re
a
d
 b
y
 1
 o
f 4
 ra
d
io
lo
g
is
ts
. 
u
s
e
d
 b
o
th
 c
o
m
p
u
te
r a
id
e
d
 d
e
te
c
tio
n
 a
n
d
 m
a
n
u
a
l d
e
te
c
tio
n
. 
R
a
d
io
lo
g
is
t in
te
rp
re
te
d
 a
n
d
 le
s
io
n
 s
iz
e
 v
a
lid
a
te
d
 b
y
 2
 ra
d
s
 a
t 
c
o
n
fe
re
n
c
e
. 
1
/2
 ra
d
s
 re
a
d
 in
itia
l s
c
a
n
. C
o
n
fe
re
n
c
e
 re
v
ie
w
e
d
 m
o
d
e
ra
te
/h
ig
h
 
s
u
s
p
ic
io
n
 s
tu
d
ie
s
.  U
s
e
d
 c
o
m
p
u
e
r a
lg
o
rith
m
 to
 c
la
s
s
ify
 p
re
-b
io
p
s
y
 
lu
n
g
 c
a
 ris
k
 
2
 ra
d
s
 re
a
d
 in
d
e
p
e
n
d
e
n
tly
. U
n
m
a
s
k
e
d
 to
 p
a
rtic
ip
a
n
t w
ith
in
 th
e
 s
tu
d
y
 
m
e
a
s
u
re
m
e
n
t o
f o
u
tc
o
m
e
s
 
p
o
o
r 
fa
ir 
fa
ir 
fa
ir 
fa
ir 
u
n
c
e
rta
in
: la
rg
e
 p
ro
p
o
rtio
n
 o
f 
fe
m
a
le
s
 w
e
re
 n
e
v
e
r s
m
o
k
e
rs
, 
m
a
jo
rity
 o
f to
ta
l p
o
p
u
la
tio
n
 w
e
re
 
n
e
v
e
r s
m
o
k
e
rs
 
fa
ir 
fa
ir 
fa
ir 
fa
ir. P
ts
 p
a
id
 fo
r w
o
rk
u
p
 
th
e
m
s
e
lv
e
s
 
g
e
n
e
ra
liz
a
b
ility
 
fa
ir 
fa
ir 
fa
ir 
fa
ir 
fa
ir 
fa
ir 
fa
ir 
fa
ir 
fa
ir 
fa
ir 
s
tu
d
y
 q
u
a
lity
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B
la
n
c
h
o
n
 
D
ie
d
e
ric
h
 
G
a
rg
 
G
o
h
a
g
a
n
 
H
e
n
s
c
h
k
e
 
In
fa
n
te
 
K
a
n
e
k
o
/S
o
b
u
e
 
L
o
p
e
s
 
P
e
g
n
a
 
M
a
c
R
e
d
m
o
n
d
 
M
e
n
e
z
e
s
 
A
u
th
o
r 
R
C
T
 (a
n
n
u
a
l L
D
C
T
 
v
s
 C
X
R
) 
p
ro
s
p
e
c
tiv
e
 c
o
h
o
rt 
(a
n
n
u
a
l L
D
C
T
 
s
c
re
e
n
) 
R
C
T
 (a
n
n
u
a
l L
D
C
T
 
v
s
 n
o
 s
c
re
e
n
in
g
) 
R
C
T
 (a
n
n
u
a
l L
D
C
T
 
v
s
 C
X
R
 2
 c
y
c
le
s
) 
p
ro
s
p
e
c
tiv
e
 c
o
h
o
rt 
R
C
T
 (a
n
n
u
a
l L
D
C
T
 
v
s
 c
o
n
tro
l) 
p
ro
s
p
e
c
tiv
e
 c
o
h
o
rt (6
 
m
o
 s
c
re
e
n
in
g
 
in
te
rv
a
l) 
R
C
T
 (L
D
C
T
 v
s
 n
o
 
s
c
re
e
n
in
g
) 
p
ro
s
p
e
c
tiv
e
 c
o
h
o
rt 
(a
n
n
u
a
l s
c
re
e
n
in
g
) 
p
ro
s
p
e
c
tiv
e
 c
o
h
o
rt 
d
e
s
ig
n
 
c
o
m
p
a
ra
b
le
 g
ro
u
p
s
 a
t ra
n
d
o
m
iz
a
tio
n
. U
n
c
le
a
r o
f ra
n
d
o
m
iz
a
tio
n
 p
ro
c
e
d
u
re
 o
r 
a
llo
c
a
tio
n
 c
o
n
c
e
a
lm
e
n
t 
- 
ra
n
d
o
m
iz
a
tio
n
 p
ro
c
e
d
u
re
 N
R
. C
o
n
tro
l g
ro
u
p
 a
p
p
e
a
rs
 to
 h
a
v
e
 g
re
a
te
r p
-y
 
h
is
to
ry
 b
u
t w
id
e
 s
ta
n
d
a
rd
 d
e
v
ia
tio
n
 s
o
 n
o
n
-s
ig
n
ific
a
n
t d
iffe
re
n
c
e
 b
e
tw
e
e
n
 
g
ro
u
p
s
 
a
p
p
ro
p
ria
te
 ra
n
d
o
m
iz
a
tio
n
 - b
lo
c
k
s
 o
f v
a
ria
b
le
 s
iz
e
 v
ia
 c
e
n
tra
l s
y
s
te
m
. 
C
o
m
p
a
ra
b
le
 b
a
s
e
lin
e
 g
ro
u
p
s
 
- 
p
e
rm
u
te
d
 b
lo
c
k
s
 o
f 4
 s
tra
tifie
d
 b
y
 c
e
n
te
r. U
n
c
le
a
r o
f a
llo
c
a
tio
n
 c
o
n
c
e
a
lm
e
n
t. 
C
o
m
p
a
ra
b
le
 b
a
s
e
lin
e
 g
ro
u
p
s
 e
x
c
e
p
t fo
r c
h
ro
n
ic
 re
s
p
ira
to
ry
 s
y
m
p
to
m
s
 in
 L
D
C
T
 
a
rm
. 
- 
ra
n
d
o
m
iz
a
tio
n
 b
y
 c
e
n
tra
l c
o
m
p
u
te
r s
y
s
te
m
. U
n
c
le
a
r c
o
n
c
e
a
lm
e
n
t. 
- - 
ra
n
d
o
m
iz
a
tio
n
/a
llo
c
a
tio
n
 c
o
n
c
e
a
lm
e
n
t 
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6
2
1
/7
6
5
 (8
1
%
) w
ith
 b
a
s
e
lin
e
 d
a
ta
 d
u
e
 to
 w
ith
d
ra
w
a
l. 
W
ith
d
ra
w
a
ls
 m
o
re
 lik
e
ly
 to
 b
e
 in
 C
X
R
 g
ro
u
p
 a
n
d
 y
o
u
n
g
e
r 
6
6
8
/8
1
7
 (8
2
%
) re
tu
rn
e
d
 fo
r re
p
e
a
t s
c
a
n
 a
t 1
 y
r 
a
ll 9
2
 ra
n
d
o
m
iz
e
d
 to
 C
T
 g
ro
u
p
 u
n
d
e
rw
e
n
t b
a
s
e
lin
e
 s
c
a
n
. 
9
6
%
 a
n
d
 8
6
%
 a
d
h
e
re
n
c
e
 in
 L
D
C
T
 g
ro
u
p
 a
t b
a
s
e
lin
e
 a
n
d
 1
 y
r 
re
s
p
e
c
tiv
e
ly
 
8
4
1
/1
0
0
0
 (8
4
%
) h
a
d
 a
n
n
u
a
l re
p
e
a
t s
c
a
n
, 1
1
7
 w
e
re
 c
o
n
s
id
e
re
d
 
d
ro
p
o
u
ts
 (1
2
%
) 
2
8
1
1
 to
ta
l ra
n
d
o
m
iz
e
d
, 2
4
7
2
 (8
8
%
) u
n
d
e
rw
e
n
t b
a
s
e
lin
e
 e
x
a
m
. 
U
n
c
le
a
r a
d
h
e
re
n
c
e
 a
t fo
llo
w
u
p
 
1
1
8
0
/1
6
1
1
 (7
3
%
) u
n
d
e
rw
e
n
t 1
s
t re
p
e
a
t. 4
4
5
 (2
7
%
) a
t 4
 y
e
a
rs
. 
1
4
0
6
/1
6
1
3
 (8
7
%
) ra
n
d
o
m
iz
e
d
 to
 L
D
C
T
 u
n
d
e
rw
e
n
t b
a
s
e
lin
e
 
s
tu
d
y
 
4
1
3
 (9
2
%
) c
o
m
p
le
te
d
 2
 y
r fo
llo
w
 u
p
 
2
6
8
6
/3
3
5
2
 (8
0
%
) re
tu
rn
e
d
 fo
r a
n
n
u
a
l re
p
e
a
t 
a
d
h
e
re
n
c
e
/d
ro
p
o
u
ts
 
6
 (1
%
) o
f th
o
s
e
 in
 
C
X
R
 g
ro
u
p
 g
iv
e
n
 
L
D
C
T
 
- - 
ra
n
d
o
m
 s
u
rv
e
y
: 1
.3
-
2
.6
%
 in
 C
X
R
 
re
c
e
iv
e
d
 C
T
. 1
3
-
2
0
%
 in
 L
D
C
T
 g
o
t 
C
X
R
 fo
r a
n
y
 re
a
s
o
n
 
- 
6
.1
%
 re
c
e
iv
e
d
 n
o
n
-
p
ro
to
c
o
l C
T
. 1
9
%
 
re
c
e
iv
e
d
 C
X
R
 
- 
n
o
t a
s
s
e
s
s
e
d
 
- - 
c
o
n
ta
m
in
a
tio
n
/c
ro
s
s
o
v
e
r 
+
+
+
: c
o
n
c
e
rn
 th
a
t th
o
s
e
 in
 C
X
R
 g
ro
u
p
 w
h
o
 d
ro
p
p
e
d
 o
u
t m
a
y
 b
e
 
h
e
a
lth
ie
r a
n
d
 le
s
s
 lik
e
ly
 to
 h
a
v
e
 lu
n
g
 c
a
n
c
e
r 
+
+
: D
u
e
 to
 fu
n
d
in
g
, s
c
re
e
n
in
g
 d
is
c
o
n
tin
u
e
d
 fo
r <
5
5
 y
o
 a
fte
r >
=
1
 
n
o
rm
a
l re
p
e
a
t s
c
a
n
 (2
 to
ta
l s
c
a
n
s
). >
5
5
 y
o
 re
p
e
a
t C
T
s
 c
o
n
tin
u
e
d
.  
O
n
ly
 n
=
2
4
 (3
%
) u
n
d
e
rw
e
n
t 5
 s
c
a
n
s
 to
ta
l.  N
=
1
4
9
 d
id
 n
o
t re
s
p
o
n
d
 
o
r d
id
 n
o
t a
g
re
e
 to
 f/u
 s
tu
d
ie
s
.  2
0
6
 to
ta
l n
o
d
u
le
s
 c
o
u
ld
 n
o
t b
e
 
fo
llo
w
e
d
 u
p
 b
c
 L
T
F
 
+
: a
ll th
o
s
e
 ra
n
d
o
m
iz
e
d
 w
e
re
 a
d
h
e
re
n
t 
+
: a
p
p
ro
p
ria
te
 d
o
c
u
m
e
n
ta
tio
n
 
+
+
: a
c
c
e
p
ta
b
le
 fo
llo
w
u
p
 ra
te
, e
x
p
la
n
a
tio
n
 o
f d
ro
p
o
u
ts
, c
o
n
ta
c
te
d
 
in
d
iv
id
u
a
ls
 w
h
o
 d
id
 n
o
t fo
llo
w
u
p
 
+
+
: a
c
c
e
p
ta
b
le
 ra
te
s
 o
f a
d
h
e
re
n
c
e
 a
n
d
 c
o
n
ta
m
in
a
tio
n
, b
u
t u
n
c
le
a
r 
a
d
h
e
re
n
c
e
 a
t 3
 y
r fo
llo
w
u
p
 
+
+
+
: fo
r p
ro
fit o
rg
a
n
iz
a
tio
n
 re
q
u
ire
s
 m
e
m
b
e
rs
 to
 p
a
y
 d
u
e
s
 fo
r 
a
c
c
e
s
s
 to
 s
c
re
e
n
in
g
, m
a
jo
rity
 s
u
b
je
c
ts
 d
ro
p
p
e
d
 o
u
t a
fte
r 3
rd
 
s
c
re
e
n
in
g
 ro
u
n
d
 (1
2
 m
o
n
th
s
 fo
llo
w
 u
p
) 
+
+
: n
o
n
 re
s
p
o
n
s
e
 
+
+
 
+
+
:  2
0
%
 o
f p
a
rtic
ip
a
n
ts
 w
h
o
 d
id
 n
o
t re
tu
rn
?
 
s
e
le
c
tio
n
 b
ia
s
 p
o
te
n
tia
l(+
 to
 +
+
+
 s
c
a
le
) 
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2
 ra
d
io
lo
g
is
ts
 re
a
d
 e
a
c
h
 s
c
a
n
 in
d
e
p
e
n
d
e
n
tly
, d
is
c
re
p
a
n
c
y
 b
y
 c
o
n
s
e
n
s
u
s
 
s
c
a
n
s
 re
a
d
 b
y
 1
 o
f 2
 ra
d
io
lo
g
is
ts
, u
n
c
le
a
r a
b
o
u
t m
a
s
k
in
g
 
re
a
d
 b
y
 1
 c
h
e
s
t ra
d
io
lo
g
is
t, s
u
s
p
ic
io
u
s
 s
c
a
n
s
 re
a
d
 in
d
e
p
e
n
d
e
n
tly
 b
y
 2
n
d
 ra
d
io
lo
g
is
t, 
c
o
n
s
e
n
s
u
s
 fo
r d
is
c
re
p
a
n
c
y
. N
o
 m
e
n
tio
n
 o
f m
a
s
k
in
g
 
re
a
d
 b
y
 ra
d
io
lo
g
is
t a
t e
a
c
h
 s
ite
. R
e
s
u
lts
 re
c
o
rd
e
d
 o
n
 s
ta
n
d
a
rd
iz
e
d
 fo
rm
s
. U
n
c
le
a
r o
f 
m
a
s
k
in
g
 o
r d
is
c
re
p
a
n
c
y
 in
 re
a
d
s
. 
e
a
c
h
 s
c
a
n
 re
a
d
 b
y
 2
 ra
d
io
lo
g
is
ts
 m
a
s
k
e
d
 to
 o
th
e
r's
 re
a
d
. A
s
s
e
s
s
e
d
 re
a
d
e
r 
a
g
re
e
m
e
n
t 
2
 c
h
e
s
t ra
d
io
lo
g
is
ts
 re
a
d
 e
a
c
h
 s
c
a
n
 in
d
e
p
e
n
d
e
n
tly
, c
o
n
s
e
n
s
u
s
 fo
r d
is
c
re
p
a
n
c
y
. 
2
 ra
d
io
lo
g
is
ts
 o
r c
h
e
s
t p
h
y
s
ic
ia
n
s
 re
a
d
 e
a
c
h
 s
c
a
n
. 2
n
d
 re
a
d
e
r n
o
t b
lin
d
e
d
 to
 firs
t 
in
te
rp
re
ta
tio
n
. 3
rd
 re
a
d
e
r d
e
te
rm
in
e
d
 re
c
o
m
m
e
n
d
a
tio
n
 fo
r th
in
 s
e
c
tio
n
 C
T
. 
C
o
m
p
u
te
r a
id
e
d
 d
ia
g
n
o
s
is
 w
a
s
 in
tro
d
u
c
e
d
 in
 m
id
d
le
 o
f tria
l. 
re
a
d
 b
y
 2
 ra
d
s
 in
d
e
p
e
n
d
e
n
tly
. D
is
c
re
p
a
n
c
y
 b
y
 c
o
n
s
e
n
s
u
s
. p
u
lm
o
n
o
lo
g
is
t w
a
s
 n
o
t 
b
lin
d
e
d
 to
 g
ro
u
p
. 
re
a
d
 b
y
 2
 ra
d
s
 in
d
e
p
e
n
d
e
n
tly
. D
is
c
re
p
a
n
c
y
 b
y
 c
o
n
s
e
n
s
u
s
. 
I-E
L
C
A
P
 p
ro
to
c
o
l -  N
o
t re
p
o
rte
d
. T
h
u
s
 d
o
 n
o
t k
n
o
w
 w
h
o
 re
a
d
 s
c
a
n
s
 
m
e
a
s
u
re
m
e
n
t o
f o
u
tc
o
m
e
s
 
fa
ir - o
n
ly
 4
1
%
 G
P
s
 p
a
rtic
ip
a
te
d
 in
 
re
c
ru
itm
e
n
t, b
u
t th
is
 w
o
u
ld
 o
n
ly
 
a
ffe
c
t g
e
n
e
ra
liz
a
b
ility
 if G
P
s
 s
e
rv
e
d
 
d
iffe
re
n
t p
o
p
u
la
tio
n
s
 
fa
ir 
p
o
o
r  (m
a
n
y
 a
lre
a
d
y
 id
e
n
tifie
d
 w
ith
 
s
p
u
tu
m
 a
ty
p
ia
 in
 p
rio
r s
tu
d
y
) 
fa
ir 
fa
ir 
fa
ir 
p
o
o
r: m
e
m
b
e
rs
h
ip
 in
 a
n
 
o
rg
a
n
iz
a
tio
n
 
fa
ir 
fa
ir 
fa
ir 
g
e
n
e
ra
liz
a
b
ility
 
fa
ir 
fa
ir 
fa
ir 
g
o
o
d
 
fa
ir 
fa
ir 
fa
ir 
fa
ir 
fa
ir 
fa
ir 
s
tu
d
y
 q
u
a
lity
 
Table 4. Quality assessment of included studies. 
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N
a
w
a
 
P
a
s
to
rin
o
 
P
e
d
e
rs
e
n
 
R
o
b
e
rts
 
S
h
a
h
a
m
 
S
o
n
e
 
S
w
e
n
s
e
n
 
V
e
ro
n
e
s
i 
W
ils
o
n
 
N
Y
-
E
L
C
A
P
 
A
u
th
o
r 
1
3
5
2
4
 
2
0
3
1
 
2
0
4
7
 
1
0
0
0
 
1
7
8
4
 
1
3
7
8
6
 
- 
1
0
0
2
2
 
7
0
6
5
 
1
2
3
0
9
 
#
 s
c
re
e
n
in
g
 
te
s
ts
 
p
e
rfo
rm
e
d
 
4
1
 
2
2
 
1
7
 
2
0
 
1
4
 
6
0
 
6
8
 
9
2
 
8
0
 
1
2
4
 
to
ta
l 
lu
n
g
 
c
a
s
 
- 
1
5
%
 (o
f 
to
ta
l 
s
c
a
n
s
) 
1
7
9
 
(8
.7
%
) 
2
6
%
 
8
.2
0
%
 
5
8
8
 
(4
.3
%
) 
- 
2
7
9
9
 
(2
8
%
) 
4
1
%
 
1
0
%
 
%
 to
ta
l 
p
o
s
itiv
e
 
- - 
2
9
%
 
- 
2
0
3
 (2
4
%
) 
- 
5
1
%
 
5
3
%
 
4
1
%
 
- 
%
 o
f b
a
s
e
lin
e
 p
a
rtic
ip
a
n
ts
 w
ith
 
a
n
y
 N
C
N
 o
n
 a
n
y
 s
c
a
n
 
(e
x
c
lu
d
in
g
 b
e
n
ig
n
) (in
c
lu
d
e
s
 <
5
 
m
m
) 
- - - 
2
6
%
 
- 
4
.9
%
 a
t b
a
s
e
lin
e
, 3
.8
%
 
a
t 1
s
t re
p
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Discussion: 
 
This systematic review attempted to characterize the harms associated with lung cancer 
screening.  Overall, harm outcomes were not uniformly reported across included studies.  In 
addition, harms were difficult to quantify as most studies did not report information or reported 
incomplete information on harms.  However, data from the included studies show that the harms 
of screening for lung cancer with low dose CT are not trivial.  Harms should warrant discussion 
when deciding whether to initiate mass screening for lung cancer even if a mortality benefit is 
observed in good quality randomized controlled trials.  For a successful screening program, the 
benefits of undergoing the screening test should outweigh the potential harms.   
Healthcare usage  
Healthcare usage following screening exam was addressed in the PLuSS study only78.  
Results showed increases in outpatient visits over the first 6 months following screening and 
then a decline to pre-screening levels by 12 months.  This short term increase could be due to 
distress of testing, participation in a study, and a motivated volunteer population.  Measures 
were self-reported so one must interpret these results with caution as recall and social biases 
may also play a role in reporting.  Further studies should explore the relationship of healthcare 
usage post screening as this is likely to play a role in the burden of testing and burden on the 
healthcare system.   
Distress/anxiety/quality of life  
Psychological factors and quality of life were mentioned in a third of included 
studies42,71,72,81,89.  Distress and anxiety were usually briefly mentioned in discussion as a 
potential psychological harm to screening, especially when a false positive result occurs.  None 
of the included studies quantified distress on a validated scale.  In the NELSON trial for which 
results are not yet published, the psychological effects of screening are specifically addressed in 
3 articles90-92.  
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In a study conducted by Bunge et al, the authors examined distress in 351 subjects 
before and after LDCT screening in the NELSON randomized trial91.  Participants were 
surveyed 1 day before screening and 6 months after using the Impact of Event Scale (IES).  
Statistically significant results were observed for participant‟s perceived risk of developing lung 
cancer before and after screening.  14.5% perceived their risk for lung cancer as high 1 day 
before screening whereas 10.5% perceived their risk to be high 6 months later (p<0.01).  Of 
note, all individuals here received a negative screening result so the results may be explained 
by reassurance in the screening group.  From this study, it is unclear how those with a false 
positive result would perceive their risk after screening.   
In a second study, the authors surveyed 351 participants who were randomized to the 
LDCT screening arm of the NELSON trial90.  Health related quality of life (HRQoL) and 
discomfort were measured 1 day before, within one week after, and 6 months post screening 
with the 12–item Short Form and the EuroQol questionnaire.  This study found that 87 to 99% of 
participants reported no discomfort related to the LDCT screening procedure and HRQoL did 
not significantly change over time, but 46% of participants reported at least some discomfort in 
waiting for results and 51% of participants reported dreading the screening exam results.  The 
authors concluded that LDCT screening demonstrated no adverse effects on quality of life but 
discomfort was observed in waiting for results.  Of note, this study excluded positive screening 
exams so does not measure the discomfort of false positives.  
In a further study, 733 participants in the NELSON trial were surveyed for health related 
quality of life, anxiety, and lung cancer specific distress before and after screening92.  Quality of 
life and anxiety measures did not change before and after screening for those with a negative 
result.  However, IES scores increased after an indeterminate result and decreased after a 
negative result.  This shows that lung cancer distress increases after receiving an indeterminate 
result and that relief occurs after a negative result.  This study excluded positive results and 
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thus could not determine the effect of a false positive result on quality of life, anxiety, or lung 
cancer specific distress.  
From these results, it is likely that distress, quality of life, and anxiety are likely to be 
important factors that should be addressed before implementing a LDCT screening program.  
This includes providing timely results and how to handle the psychological effect of an 
indeterminate result.  None of these three studies addressed false positive results, which likely 
increase anxiety and lung cancer specific distress even further than an indeterminate result.  
False positives and false negatives   
One third of studies reported any false negative findings.  False negatives were not 
uniformly defined.  I included false negatives as they were defined in the primary studies.  This 
definition included cancers detected on incident screen that were visible on prior screening 
exam, interim cancers that were visible on prior exam, and any cancers missed on CT but 
diagnosed by other means.  Veronesi and Sone reported high numbers of false negative cases, 
24 and 18 respectively, whereas other studies reported fewer than 5 cases43,69.  In a follow up 
study, Li et al describes the errors in interpretation and detection as the primary causes for 
missing these lung cancers93.   
I was able to determine the false positive rate for all included studies.  I defined false 
positives as screening exams that were interpreted as positive, according to the study definition 
of a positive test, but did not result in a diagnosis of lung cancer.  For the majority of studies, at 
least 9 out of 10 positive screening tests were false positives at baseline.  In addition, Croswell 
et al showed that the probability of having a false positive result after 2 total scans was 33% in 
the LSS population84.  This study was conducted in a high risk population with >30 pack-years 
and >55 years old.  However, this high proportion of those with a false positive test after 2 years 
increases burden on both the individual and the healthcare system as a positive result requires 
further medical evaluation with uncertain benefit.  
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These results show the poor predictive value of LDCT in screening for lung cancer.   By 
changing the definition of a positive result, investigators hoped to decrease the false positive 
rate as was done in the ELCAP study94.  However, the false positive rates in I-ELCAP and NY-
ELCAP were still 90% and 88%, respectively38,61.  The lowest false positive rate at baseline was 
86% in the DANTE trial where the definition of a positive result was any abnormality of 
malignancy which included NCN ≥10mm or smaller with suspicious features56.  This definition 
has a greater cutoff than other definitions as most studies defined a positive result as any NCN 
≥5mm.  Thus one would expect a smaller degree of false positives with an increased size cutoff.  
Furthermore, in the DANTE trial there were 13 interim cancers diagnosed because of symptoms 
out of 63 total, representing a higher proportion of symptom diagnosed cancers than other 
studies56.  These data demonstrate that LDCT screening is not without false negative exams 
and has a high proportion of false positive cases, even when a strict definition of a positive 
result is used in a high risk population.   
Surgeries for benign disease  
Most studies reported surgeries resulting in a benign diagnosis, however the proportion 
of these from total surgeries was variable with a few studies reporting none and others reporting 
more than 30% with most falling in the 20-30% range.  Most studies had a recommended 
workup protocol after a positive result, but a uniform protocol across the studies did not exist.  
Furthermore, the treating physician usually had full discretion to follow the recommendation for 
further medical evaluation.  The majority of follow up included further imaging, usually high 
resolution CT, diagnostic CT, or PET scan.  No uniform rule existed for when to biopsy, or 
whether the biopsy should be non-surgical or surgical.  As a result of the variability among 
workups, one would expect variable rates of surgery for benign disease.  The studies that had 
the least rates of surgeries for benign disease used strict workup algorithms before surgery.  
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Morbidity and mortality of workup   
Complications were incompletely reported as only half of the studies reported observed 
morbidity and mortality for diagnosis or treatment.  Studies reported complications of biopsy 
including pneumothorax, infection, respiratory failure, and stroke.  Nine total deaths related to 
follow up were reported in total.  In a follow up article to the Mayo study, the authors reported 
complications of workup and treatment73.  The complication rate in this study was 27%, a value 
higher than that reported in any other study.  The Lung Screening Study reported the next 
greatest number of complications related to follow up with 10 total complications, representing a 
much lower percentage than that in the Mayo study81,82.  From this information, it is likely that 
complications of workup are underreported in the included studies and further studies should 
seek to report complications of work up including non-surgical and surgical biopsy.  This 
information is vital to quantifying harms of lung cancer screening workup.  
Incidental findings  
Seven out of the 20 included studies reported any incidental findings.  Clinically relevant 
findings were reported at a rate of 7 to 49% among the seven studies.  Thus, IFs were 
underreported and variable.  The ELCAP study reported a prevalence of 0.77% of mediastinal 
masses in the study cohort62 whereas MacRedmond reported that 62% of those screened had 
an incidental finding on LDCT screening79,80.  It appeared that only the PALCAD study 
completely reported incidental findings, including those that did and did not require further 
workup79,80.  The Mayo study reported only clinically relevant findings but I could not determine 
the proportion of those screened with an incidental finding44,45,72.   
Incidental findings were explored as part of the NELSON study95.  In 1929 participants 
who underwent LDCT, 129 were deemed to have clinically relevant findings that required further 
workup.  After workup, only 21 had confirmed clinically important findings.  Most were cysts and 
one malignancy was detected.  As a result, the authors advised against searching for incidental 
findings which contradicts the results found in the PALCAD and Mayo studies.  Importantly, the 
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NELSON authors did not report on aneurysms, bronchiectasis, emphysema, or coronary 
calcifications.   From this information, it appears there is selective reporting of incidental 
findings, with investigators attempting to report all IFs and others reporting only those they 
deem clinically relevant.   Incidental findings may require further workup which adds to the 
testing burden at unknown benefit to the individual and population.  However, incidental findings 
are an important part of the burden of testing that should be taken into account when deciding to 
implement a mass screening program.  As a result, additional research should be undertaken in 
future trials as incidental findings in lung cancer screening likely need to be further explored.  
Radiation dose  
Harmful effects of radiation were addressed in several studies39,42,43,67,71,72.  The reported 
effective dose ranged from 0.6 to 1.5 mSv.  Diederich estimated that the radiation exposure 
from screening cohort could induce 3-6 additional lung cancers in 15-20 years39,40,96.   This dose 
is also cumulative over time.  If high risk smokers underwent annual screening starting at age 
50, Brenner estimated that LDCT exams would increase lung cancers by 1.8% (CI: 0.5%, 5.5%) 
due to radiation induced lung cancers from screening97.  Thus, the risk of radiation is likely non-
negligible and should be considered when attempting to implement a lung cancer screening 
program.  
Overdiagnosis   
Overdiagnosis represents a significant potential concern to implementing a mass 
screening program.  Few studies provided estimates on the proportion of overdiagnosed 
cancers.  Lindell et al reported that 13 of 48 CT detected cancers may have been 
overdiagnosed in the Mayo study as all had volume doubling times >400 days98 (330).  Autopsy 
data from Dammas et al and Manser et al suggest that overdiagnosis may play a role99,100.  
Dammas found that 25% of nodules detected on CT were not identified at autopsy, suggesting 
that incidental lung cancers are not identified even at autopsy99.  Manser found that the majority 
of incidental lung cancers detected at autopsy were stage I100.  In a critical appraisal of 
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overdiagnosis in lung cancer screening, Reich et al estimated that 25% of chest x-ray identified 
cancers were overdiagnosed101.  As CT detects more cancers, it is likely that a greater 
proportion of cancers are overdiagnosed with CT.  Thus, overdiagnosis of indolent lung cancers 
that never would be a problem in a person‟s lifetime are likely to play a significant role in the 
harms of screening for lung cancer and should be taken into account as a contributing harm.  
Limitations of this review  
I conducted the research for this review in its entirety which can introduce bias.  A good 
quality systematic review requires at least two investigators and uses independent review with 
third party or group consensus for discrepancies for abstract and full text inclusion, data 
abstraction, and quality appraisal.  It was unclear if I included all studies published in other 
countries as I only included English studies.  There also exists a potential publication bias as I 
did not seek to find unpublished data.  
Limitations of the evidence  
Studies variably reported harm outcomes.  It was difficult to accurately determine true 
rates of procedures for benign disease, morbidity/mortality of workup, false negatives, and 
incidental findings.  Harms are necessary to balance the risks and benefits of a screening test 
and thus it is difficult to make conclusions based on incomplete evidence.  
In addition to variable reporting of desired outcomes, study populations, definition of a 
positive, and workup algorithms were inconsistent.  Study populations were heterogeneous as 
age and tobacco exposure varied across the studies.  For a positive definition, some studies 
included all NCNs whereas others included only NCNs ≥5mm.  Other studies used a vague 
definition, such as „a nodule suspicious for lung cancer.‟  Thus, it is difficult to compare positivity 
rates across studies without a standardized definition.  The workup algorithm for positive results 
also differed among the included studies.  Studies usually included a recommendation for 
further workup based on the suspiciousness of the test result but participants and providers did 
not necessarily adhere to follow up recommendations.    
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Implications for practice   
Currently no groups recommend mass screening for lung cancer.  However, the NLST 
reportedly has demonstrated a 20% reduction in mortality for the LDCT screening arm 
compared to the control arm.  Thus, it is likely that this mortality benefit will require policy 
makers to address lung cancer screening.  Clinicians will need to consider both the harms and 
benefits of screening for lung cancer and balance the tradeoffs so that the benefits outweigh the 
harms.   
Implications for research  
Harm data was incompletely reported.   Future trials should fully report on harms of 
screening.  Questions that have yet to be worked out include the following:  
(a) What is the most effective screening frequency? 
(b)  What is the appropriate level of risk to start screening based on age and exposure 
status?  
(c) What is the best collimation of the LDCT exam?    
(d) What is the most effective protocol for minimizing testing burden and unnecessary 
procedures?  
In addition, a protocol for follow up after a positive test should be standardized so that 
both clinicians and patients know what to expect.  I anticipate final results from randomized trials 
currently underway will help address these issues. 
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Conclusion:  
The best screening test has the most beneficial tradeoff between harms and benefits.  
The benefits of screening are important, but in order to make informed decisions clinicians must 
be aware of the harms as well.  Evidence collected in this review shows that harms of lung 
cancer screening are non-negligible to both the individual and the health care system.  Even 
though there is evidence that harms must be considered, there is insufficient evidence to make 
a recommendation on what level of benefit is required to outweigh the harms of screening.  
Clinicians, policy-makers, and patients must weigh both before considering implementing a 
LDCT lung cancer screening program.  I anticipate the final results of the NLST and other 
randomized trials to help address these concerns.  
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Appendix A: Introduction  
Lifetime lung cancer incidence is 1 in 13 for men and 1 in 16 for women9.  In 2007, lung 
cancer incidence was 69.9 cases per 100,000 person-years for males and 51.6 cases per 
100,000 person-years for females13.  The combined incidence for this year was 59.3 cases per 
100,000 person-years13.  Incidence among males has trended downward, from a peak of 102.0 
cases per 100,000 person-years in 1984 whereas incidence among females has trended 
upward from 39.5 cases per 100,000 person-years in 198413.  Mortality rates from lung cancer 
in 2007 were 65.2 deaths per 100,000 person-years in males and 40.0 deaths per 100,000 
person-years in females13.  Combined mortality was 50.7 deaths per 100,000 person-years in 
200713.  Mortality in males has trended down since a peak in 1987 where the mortality rate was 
90.1 deaths per 100,000 person-years whereas mortality in females has increased since the 
1970s until about 2000 where it stabilized at 40 deaths per 100,000 person-years13.  
Former smokers have significant smoking histories placing these individuals at 
increased risk for developing lung cancer.  A 55 year old one pack per day smoker with a 25 
year history of smoking has a 1% probability of developing cancer over the next 10 years102.  If 
this person quits and remains abstinent for the next 10 years, the risk of developing lung cancer 
decreases to <1%102.  This risk increases to 14% over the next 10 years for a 65 year old 
smoker with a 50 year history of smoking 2 packs per day102.  If this person quits, he or she can 
decrease their risk to 10% over the next 10 years102.  This demonstrates the dose dependent 
relationship between the exposure time (years smoking) and the magnitude of exposure 
(number cigarettes per day).  As a result, it is expected that many new cases of lung cancer will 
be diagnosed in the coming years.   
The 5 year survival of all stages of lung cancer is 16%8.  The greatest survival is seen in 
early stages with 53% surviving at 5 five years8.  However, survival rates can be biased 
measurements of improvement in prognosis.  Instead of serving as a proxy for improving 
treatments, changes in survival rates often suffer from changing patterns of diagnosis103.  Even 
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though trends of 5 year survival may improve from detection of early stage cancers in 
uncontrolled observational studies, this does not necessarily equate to an improvement in 
treatment or mortality.  Lead time bias, length time bias, and overdiagnosis often plague the 
measurement of 5 year survival because it is often measured from observational studies103.  
Improvement in survival rates may be because we are diagnosing more cancers unnecessarily 
rather than improving the prognosis.  As a result, I report incidence and mortality rates for lung 
cancer among males and females rather than 5 year survival rates.  
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Appendix B: Methods 
To determine if a review of harms was indicated, I searched the DARE, CDSR, and NGC 
databases for reviews of lung cancer screening with low dose CT.  Using the search term „lung 
cancer screening‟ in DARE yielded 77 titles (21 DARE, 34 NHS, 22 HTA).  Each title and 
abstract was reviewed for relevance to lung cancer screening with low dose CT.  If studies were 
relevant by abstract, one reviewer read each full text to determine the relevance of the review to 
LDCT screening harms.  Reviews and cost-effectiveness studies have mentioned harms, but 
none have focused on harms as a primary outcome.  Some reviews focus on individual harms, 
but do not include all potential harms.    
Search Strategies: 
MEDLINE: search keywords 
(lung cancer OR “Lung Neoplasms” [MeSH Terms]) AND (early detection of cancer OR mass 
screening OR early diagnosis) AND "tomography, x-ray computed"[MeSH Terms] OR 
“tomography, spiral computed” [MeSH Terms] OR “low dose CT“ OR “reduced dose CT” AND 
(harm OR harms OR risk OR morbidity OR false positive OR false negative OR overdiagnosis 
OR unnecessary OR quality of life OR incidental finding OR incidentaloma OR excess radiation 
OR repeat imaging OR anxiety OR stigma) Limits: Humans, English 
EMBASE: search keywords 
(lung cancer OR Lung Neoplasms) AND (early detection of cancer OR mass screening OR 
early diagnosis) AND ("tomography, x-ray computed"  OR “tomography, spiral computed” OR 
“low dose CT“ OR “reduced dose CT”) AND (harm OR harms OR risk OR morbidity OR false 
positive OR false negative OR overdiagnosis OR unnecessary OR quality of life OR incidental 
finding OR incidentaloma OR excess radiation OR repeat imaging OR anxiety OR stigma) OR 
(lung cancer OR Lung Neoplasms) AND (early detection of cancer OR mass screening OR 
early diagnosis) AND ("tomography, x-ray computed" OR “tomography, spiral computed”) AND 
(“low dose” OR “low dose CT“ OR “reduced dose CT”) 
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CENTRAL: search keywords 
(lung cancer OR Lung Neoplasms) AND (early detection of cancer OR mass screening OR 
early diagnosis) AND "tomography, x-ray computed" OR “tomography, spiral computed” OR 
“low dose CT“ OR “reduced dose CT” AND (harm OR harms OR risk OR morbidity OR false 
positive OR false negative OR overdiagnosis OR unnecessary OR quality of life OR incidental 
finding OR incidentaloma OR excess radiation OR repeat imaging OR anxiety OR stigma) 
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Appendix C: Results 
Depiscan – Blanchon54 
The Depiscan randomized trial compares annual LDCT with chest x-ray.  The trial 
enrolled asymptomatic individuals 50-75 years old who smoked >15 cigarettes per day for >20 
years.   Enrollees were recruited from the care population of general practitioners involved in the 
study.  A total of 765 individuals were randomized with 385 in the LDCT group and 380 in the 
CXR group.  336 of those in the LDCT group underwent the baseline LDCT screening exam.  
71% were males, median age was 56 years, median smoking history was 30 pack-years, and 
64% were current smokers.  A positive screening result was defined as any NCN without benign 
features.  Only baseline screening results have been published to date.  
A total of 336 LDCT screening tests were performed.  Baseline positivity rate was 45%.  
The study reported 8 lung cancers detected at baseline.  Prevalence was 2.38%.  38% of the 
cancers were stage I at diagnosis and 63% were histologically adenocarcinoma.   
The study did not report on the randomization procedure or allocation concealment.  
Groups were comparable at randomization.  19% of those randomized dropped out before the 
baseline screening exam.  Withdrawals were more likely to be younger and assigned to the 
CXR group.  1% of those in the CXR group received a LDCT screening exam.  There is a 
concern for selection bias given the non-comparability of those who dropped out compared to 
those who adhered to the study protocol.  Those who dropped out may be healthier and less 
likely to have lung cancer.  Two radiologists read each scan independently with discrepancy 
resolved by consensus.  Overall, quality was rated as fair with fair generalizability.   
Colorado – Garg55  
This study is a pilot randomized trial comparing LDCT with no screening in a small 
sample of individuals.  The trial enrolled individuals classified as moderate risk who were 50-80 
years old with >30 pack-year history from the VA population in Denver, Colorado and individuals 
classified as high risk with COPD and known sputum atypia who were previously enrolled in a 
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cohort study.  Out of the 304 eligible participants, 239 agreed to participate and 190 were 
randomized.  Ninety-two were randomized to the LDCT group and 98 to the control group.  All of 
those in the LDCT group underwent baseline exam.  97% of the participants were male.  I could 
not determine overall smoking exposure history for the participants.  A positive result was 
defined as any NCN without benign features.  Only baseline screening results have been 
published.  
A total of 92 LDCT screening tests were performed.  Baseline positivity rate was 33%.  
The study reported 3 lung cancers detected.  Prevalence was 3.26%.   I could not determine the 
proportion of stage I and adenocarcinomas among the three cancers.  
The study did not report on the randomization procedure or allocation concealment.  The 
control group had a higher non-significant pack-year history than the screening group, but 
confidence intervals were not precise.  All those randomized to the LDCT screening group 
underwent baseline exam.  Crossover assessment was not reported.  Scans were read by one 
chest radiologist with suspicious scans read independently by a second radiologist.  Consensus 
was used for discrepancy.  Masking of investigators to the study was not mentioned.  Quality 
was rated as fair with poor generalizability given the high risk population of known sputum 
atypia and small sample size.  This is supported by the high prevalence of lung cancer found in 
the small screened population.   
DANTE - Infante56-58 
The DANTE trial began in 2001 in Italy as a randomized controlled trial comparing LDCT 
with usual care.  Recruitment took place by general practitioners, mass mailings, and media 
advertisements.  All participants received sputum cytology and chest x-ray at baseline.  The trial 
enrolled males 60-75 years old with greater than a 20 pack-year smoking history.  Median age 
was 65 years old, 56% were current smokers, and overall median smoking exposure was 47 
pack-years.  A total of 2811 eligible participants were randomized with 2472 undergoing the 
baseline exam, 1276 in the LDCT arm and 1196 in the control arm.  A positive result was 
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defined as an abnormality of malignancy including NCNs >10 mm or smaller with suspicious 
features. A scan was negative for NCNs <5mm.  
A total of 3612 LDCT screening tests were performed.  Baseline positivity rate was 16%.  
The study reported 63 lung cancers detected, 28 at baseline and 19 incident with 13 interim 
cases.  Prevalence was 2.19%.   Stage I disease was detected in 65% of those with cancer and 
43% of total cancers were adenocarcinomas.  
Adequate randomization was conducted using permuted blocks with a central system.  
Allocation concealment was unclear.  Groups were comparable at baseline for age and smoking 
exposure, but the LDCT group had a higher percentage of co-morbid respiratory conditions.  Of 
those randomized, 88% underwent the baseline exam.  The study did not report adherence at 3 
year follow up.  A survey was conducted for a subset of participants to assess for crossover 
contamination.  The authors reported 6.1% of participants received a non-protocol CT and 19% 
received a non-protocol CXR, but it was unclear if more control groups received a CT or vice 
versa so differential contamination was unable to be determined.  Scans were read by two chest 
radiologists independently with discrepancy resolved by consensus.  Quality was rated as fair 
with fair generalizability. 
ELCAP - Henchske36,37 
The Early Lung Cancer Action Project prospective study recruited 1000 asymptomatic 
volunteers from physician offices and hospitals in New York.  Participants were >60 years old 
with >10 pack-year smoking history.  Median age was 67 years old, 54% were male, and 
median smoking exposure was 45 pack-years.  A positive result was defined as 1-6 NCNs 
without benign features.  
A total of 2184 LDCT screening tests were performed.  Baseline positivity rate was 23%.  
The study reported 36 lung cancers, 27 at baseline and 7 at incident screening with 2 interim 
cases.  Prevalence was 2.70%.   82% of the cancers were stage I at diagnosis and 68% were 
histologically adenocarcinoma.   
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Of the baseline participants, 84% completed the first annual repeat scan.  The study 
reported loss to follow up for 12% of baseline participants and explained reasons for dropout 
demonstrating acceptable adherence.  Individuals were contacted who did not follow up.  Scans 
were interpreted independently by two radiologists and it was unclear how discrepancies were 
resolved.  Overall, quality was rated as fair with fair generalizability.   
NY-ELCAP61  
The New York Early Lung Cancer Action Project prospective study was a follow up study 
to the original ELCAP.  This study recruited 6295 volunteers from the New York area via media 
and physician referral.  I could not determine if there was overlap between the study cohorts so 
this study was treated as a separate study.  Participants were >60 years old with >10 pack-year 
smoking history.  Median age was 66 years old, 49% were male, 33% were current smokers, 
and median smoking exposure was 40 pack-years.  A positive result at baseline was defined as 
at least one solid or part-solid NCN ≥5mm or nonsolid NCN ≥8mm.  Repeat screening defined a 
positive screening exam as any new NCN or growth regardless of size.   
A total of 12,309 LDCT screening tests were performed.  Baseline positivity rate was 
14%.  The study reported 124 lung cancers, 101 at baseline and 20 at incident screening with 3 
interim cases.  Prevalence was 1.60%.  93% of the cancers were stage I at diagnosis and 60% 
were histologically adenocarcinoma.   
Of the baseline participants, 82% completed the first annual repeat scan.  The study 
reported the demographics of those who completed baseline and annual follow up exams and it 
appears that those who followed up were similar with respect to age, gender, and smoking 
status.  Scans were interpreted independently by two radiologists and it was unclear how 
discrepancies were resolved.  Overall, quality was rated as fair with fair generalizability.  Of 
note, the patients paid for workup themselves, which has the potential to affect dropouts and 
selection bias if those unwilling to pay do not follow up. 
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Matsumoto - Sone43,63,64  
The Matsumoto prospective study recruited 5483 volunteers from the general population 
via media advertising.  Participants were between 40 and 74 years old and included never 
smokers.  Mean age was 64 years old, 54% were male, and 46% were current and former 
smokers.  This study defined current and former smokers as those with >1 pack-year exposure 
history.  93% of females were never smokers.  Scans were classified into three categories: 
possible for cancer, probable for cancer, or a small nodule <3 mm.  
A total of 13,786 LDCT screening tests were performed.  Baseline positivity rate was 
5.1%.  The study reported 60 lung cancers, 22 at baseline and 36 at incident screening with four 
interim cases.  Prevalence was 0.40%.  88% of the cancers were stage I at diagnosis and 85% 
were histologically adenocarcinoma.  52% of the cases were diagnosed in never smokers.  
Of the 5483 participants at baseline, 80% completed the 1st annual repeat scan and 70% 
completed the 2nd repeat scan for a dropout rate of 30%.  The study reported the demographics 
of those who completed the exams for each year and it appears that those who followed up 
were similar to baseline with respect to age and smoking status.  Scans were interpreted by one 
of four radiologists with a second read conducted for suspicious or clinically significant scans 
thus the second readers were not masked to the first.  Overall, quality was rated as fair with 
uncertain generalizability given the large proportion of never-smoking females, the overall 
majority was never smokers, and the majority of cases were diagnosed in never smokers.  
ALCA – Sobue/Kaneko42,65 
Two separate studies were published from the Anti-Lung Cancer Association (ALCA) 
prospective cohort LDCT screening project which began in 1993.  This study enrolled members 
of the ALCA who were recruited from the general population to join a for profit organization that 
provided lung cancer screening to dues paying members.  Included in the study were those 40-
79 years old.  88% were male and 86% had any smoking history (thus 14% were non-smokers).  
A total of 1611 subjects were screened at baseline with LDCT (71 additional individuals had a 
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baseline screen but did not fit the age criteria for inclusion in the study).  This study also 
screened its individuals with CXR and sputum cytology in addition to LDCT at 6 month intervals.  
A total of 9502 LDCT screening tests were performed.  Baseline positivity rate was 12%.  
The study reported 36 lung cancers, 14 at baseline and 22 at incident screening with no interim 
cases.  Prevalence was 0.87%.  78% of the cancers were stage I at diagnosis and 67% were 
histologically adenocarcinoma.   
All baseline participants received a screening exam and 73% returned for a 6 month 
follow up screen.  Adherence dropped to less than 50% after 3 scans at 12 months and to 27% 
after 8 scans.  It is unclear if those who adhered to the study were different from those who 
withdrew.  This study has the potential for selection bias due to the overall poor adherence and 
limited generalizability due to its recruiting strategy in a membership organization.  
Measurement of scans was performed by 2 radiologists or chest physicians with the second 
reader aware of the first interpretation.  A third reader determined the recommendation for 
undergoing further workup.  In the middle of the study, a computer aided detection system was 
introduced which changed the reading protocol.  The study was rated as fair quality with poor 
generalizability given the membership in the organization.  
ITALUNG – Lopes Pegna66 
The ITALUNG study is a randomized trial comparing LDCT with no screening conducted 
in Italy.  The trial recruited individuals by invitation of patients registered with general 
practitioners.  Eligibility included those who were 55-69 years old with at least a 20 pack-year 
smoking history.  A total of 3206 individuals were enrolled and randomized, 1613 to the LDCT 
group and 1593 to the control group.  13% of those in the intervention arm did not undergo the 
baseline LDCT exam.  Half of the participants were male, mean age was 61 years old, median 
smoking exposure was 39 pack-years, and 65% were current smokers.  A positive result was 
defined as at least one solid NCN ≥5 mm or nonsolid NCN ≥10 mm or any part solid NCN.  Only 
baseline screening results have been published.  
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A total of 1406 LDCT screening tests were performed.  Baseline positivity rate was 30%.  
The study reported that 21 lung cancers were detected.  Prevalence was 1.42%.   Stage I 
disease was detected in 48% of individuals with cancer and 48% were adenocarcinomas.  
Adequate randomization was performed using a central computer system.  Allocation 
concealment was unclear.  87% of those assigned to the LDCT screening group underwent the 
baseline exam.  Crossover was not assessed.  There is a concern for selection bias here if 
those who did not undergo the baseline exam had different risk factor profiles for lung cancer 
than those that underwent the exam.  Scans were read independently by 2 radiologists with 
discrepancy resolved for consensus.  Quality was fair with fair generalizability.  
COSMOS - Veronesi67-69 
The COSMOS LDCT screening study recruited 5201 asymptomatic volunteers at a 
single center in Milan, Italy.  Participants were >50 years old with >20 pack-year smoking 
histories.  Mean age was 58 years old, 66% were male, and 80% were current smokers.  
Median exposure was 44 pack-years.  A positive result was defined as any NCN detected on a 
screening exam.  
A total of 5201 baseline LDCT screening tests were performed.  Baseline positivity rate 
was 53%.  The study reported 92 lung cancers, 55 at baseline and 36 at incident screening with 
one interim case.  Prevalence was 1.06%.  66% of the cancers were stage I at diagnosis and 
68% were histologically adenocarcinoma.  
Of the 1520 participants at baseline, 93% completed the annual repeat scan for a good 
level of adherence.  Scans were interpreted using both computer aided and manual detection by 
a single radiologist.  Lesion size and characteristics were discussed at conferences by a team of 
physicians which included radiologists and surgeons.  Overall, quality was rated as fair with fair 
generalizability as we do not know how the subjects were recruited. 
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Munster - Diederich39,40,70  
This prospective study recruited 817 asymptomatic volunteers at the University of 
Munster in Germany using media advertising.  Participants were >40 years old with >20 pack-
year smoking histories.  Median age was 53 years old and 72% were male.  Median exposure 
was 45 pack-years.  A positive result was defined as any NCN without benign features detected 
on a screening exam.  
A total of 2552 baseline and repeat LDCT screening tests were performed.  Baseline 
positivity rate was 46%.  The study reported 29 lung cancers, 12 at baseline and 10 at incident 
screening with seven interim cases.  Prevalence was 1.35%.  56% of the cancers were stage I 
at diagnosis and 41% were histologically adenocarcinoma.  
Of the 817 participants at baseline, 82% returned for the first annual repeat scan 
demonstrating acceptable adherence.  However, 3% of baseline participants had 5 total 
screening tests.  Selection bias is likely to play an important role in the interpretation of the 
study results as funding was discontinued for those <55 years old after one normal repeat scan.  
Those older than 55 years continued repeat scans.  This could introduce differential follow up 
issues as those >55 years old are more likely to have longer exposure to smoking and thus 
more likely to develop lung cancer.  Scans were interpreted by one of two radiologists and team 
consensus for indeterminate lesions with unclear masking to the study.  Overall, quality was 
rated as fair with fair generalizability however one should use caution due to selection bias.  
Hitachi - Nawa41 
The Hitachi prospective study recruited 7956 Hitachi employees in Japan for low dose 
CT lung cancer screening.  Participants were 50-69 years old, 79% were male, and 62% were 
current or former smokers with 38% never smokers.  A result was positive if a scan had a NCN 
≥8mm without benign features.   
A total of 13,524 screening tests using LDCT were performed.  Baseline positivity rate 
was 26%.  The study reported 41 lung cancers, 37 at baseline and 4 at incident screening with 
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no interval cases.  One individual had 2 primary lung cancers. Prevalence was 0.45%.  85% of 
the cancers were stage I at diagnosis and 85% were histologically classified as 
adenocarcinoma.  57% of the cancers were detected in non-smoking individuals.  
Of the participants at baseline, 70% returned for at least one follow up exam which is 
poor adherence compared to other included trials.  Inclusion criteria were not reported.  With a 
30% dropout rate and unclear inclusion criteria, one must consider selection bias in this cohort, 
especially with 38% never smokers.  The scans were read independently by 2 radiologists with 
discrepancy resolved at weekly conferences so measurement is on par with other studies.  
Overall, quality was rated as fair with poor generalizability.  
Milan - Pastorino71 
This prospective LDCT screening study recruited 1035 asymptomatic volunteers using 
media in Lombardy, Italy.  Participants were >50 years old with >20 pack-year smoking 
histories.  Median age was 58 years old and 71% were male.  86% and 14% were current and 
former smokers, respectively, with an overall median 40 pack-year history.  A positive result was 
defined as a NCN ≥5mm detected on a screening exam.  
A total of 2031 baseline and repeat LDCT screening tests were performed.  Baseline 
positivity rate was 19%.  The study reported 22 lung cancers, 11 at baseline and 11 at incident 
screening with no interim cases.  Prevalence was 1.06%.  77% of the cancers were stage I at 
diagnosis and 77% were histologically adenocarcinoma.  
Of the 1035 participants at baseline, 96% completed the 1st annual repeat scan with 
overall 91% compliance at follow up.   The study reported appropriate descriptions of recruiting 
procedures and adherence.  Scans were independently interpreted by two radiologists with 
interpretation by a third radiologist for discrepancies.  Overall, quality was rated as fair with fair 
generalizability.  
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Mayo Clinic - Swensen44,45,72 
The Mayo LDCT screening study recruited 1520 volunteers via media outlets at the 
Mayo Clinic in Minnesota.  Participants were >50 years old with >20 pack-year smoking 
histories.  Median age was 59 years old, 52% were male, 61% were current smokers, and 39% 
were former smokers with an overall median 45 pack-year history.  A positive result was defined 
as any NCN detected on a screening exam.  
A total of 1520 baseline LDCT screening tests were performed.  Baseline positivity rate 
was 51%.  The study reported 68 lung cancers, 31 at baseline and 34 at incident screening with 
three interim cases.  Prevalence was 2.04%.  57% of the cancers were stage I at diagnosis and 
53% were histologically adenocarcinoma.  
Of the 1520 participants at baseline, 98% completed the 1st annual repeat scan, 96% 
completed the 2nd repeat scan, 95% completed the third, and 80% completed the fourth for 
overall good adherence. The study reported only one person of the 1520 was lost to follow up.  
The investigators attempted to control for selection bias and differential adherence by 
maintaining appropriate contact with subjects.  Scans were interpreted by one of four 
radiologists with no apparent second interpretation.  Overall, quality was rated as fair with fair 
generalizability.  
PLuSS - Wilson76,77 
The PLuSS prospective study recruited 3642 volunteers via the media at the University 
of Pittsburgh in Pennsylvania.  Participants were 50-79 years old with > 12.5 pack-year smoking 
history.  There was no requirement for these individuals to be asymptomatic.  Mean age was 59 
years old, 51% were male, median smoking exposure was 47 pack-years, and 60% were 
current smokers.  A positive result was described as any NCN detected on a screening exam.   
A total of 7065 screening tests using LDCT were performed.  Baseline positivity rate was 
41%.  The study reported 80 lung cancers, 53 at baseline and 24 at incident screening with 
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three interim cases.  Prevalence was 1.46%.  Half of cancers were stage I at diagnosis and an 
unknown proportion were adenocarcinomas.  
Of the baseline participants, 95% received a repeat screening exam for a good level of 
adherence.  The scans were read by 1 of 2 radiologists and moderate and high suspicion 
studies were discussed in conferences.  A computer algorithm was used to classify pre-biopsy 
risk of lung cancer.  I could not determine the validity of this algorithm from included information.  
Overall, quality was rated as fair with fair generalizability.  
PALCAD - MacRedmond79,80 
The ProActive Lung Cancer Detection (PALCAD) prospective study recruited 449 
asymptomatic individuals via the media from the local community in Dublin, Ireland.  
Participants were >50 years old with > 10 pack-year smoking history and still smoking at 45 
years old.  Median age was 56 years old, 50% were male, median smoking exposure was 45 
pack-years, and 68% were current smokers.  A positive result was described as any non-
calcified nodule detected on a screening exam.   
A total of 1371 screening tests using LDCT were performed.  Baseline positivity rate was 
23%.  The study reported 6 lung cancers, 2 at baseline and 3 at incident screening with one 
interim case.  Prevalence was 0.45%.  Half of the 6 cancers were stage I at diagnosis and 1 of 
the six was an adenocarcinoma. 
Of the 449 participants at baseline, 92% completed the 2 year follow up for a good level 
of adherence.  The scans were read independently by 2 radiologists with discrepancy resolved 
by consensus so measurement is on par with other studies.  Overall, quality was rated as fair 
with fair generalizability.  
LSS – Gohagan81,82 
The Lung Screening Study is a randomized trial comparing LDCT with chest x-ray for 
lung cancer screening.  This trial enrolled volunteers recruited via mass mailing and referral who 
were 55-74 years old and had >30 pack-year smoking history from six PLCO centers around the 
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United States.  Participants were excluded if they were already enrolled in the PLCO trial.  59% 
were male with a median smoking history of 54 pack-years.  58% were current smokers.  Of the 
4828 eligible participants contacted, 3318 were included in the study and randomized.  1660 
were assigned to receive LDCT and 1658 were assigned to receive CXR.  A positive screen 
was defined as any NCN >3 mm or other suspicious abnormality.  
A total of 2984 LDCT screening tests were performed at baseline and annual repeat 
screening.  Baseline positivity rate was 21%.  The study reported 40 total lung cancers detected 
in the LDCT arm, 30 at baseline, 8 on repeat screen, and two interim cases.  Prevalence was 
1.89%.  48% of the cancers diagnosed were stage I and 60% were adenocarcinomas.  
The study reported an adequate randomization procedure with blocks of variable size 
randomized by a central system with adequate allocation concealment.  Groups were 
comparable at baseline for demographic information including smoking exposure and age.   
96% of those randomized to the LDCT screening group underwent baseline exam and 86% 
underwent the annual repeat study for an acceptable level of adherence.  Crossover was 
assessed using a survey sent to a random sample of participants.  1.3% to 2.6% in the CXR 
group received a CT scan during the study period whereas 13-20% of those in the LDCT arm 
received a CXR for any reason during the study period.  Scans were read by a single radiologist 
at each study site.  Results were recorded on a standardized form.  I could not determine if 
masking was implied.  Quality was rated as good with fair generalizability.  
Toronto – Menezes85 
The Toronto prospective study recruited 3352 asymptomatic participants who were 
volunteers who referred by a physician in Toronto, Canada.  Participants were >50 years old 
with >10 pack-year smoking history.  Median age was 60 years old, 46% were male, and 
median smoking exposure was 30 pack-years.  A positive result was described as at least 1 
solid/part-solid NCN ≥5 mm or non-solid NCN ≥8 mm on baseline and any growth or new NCN 
on repeat screening.  
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A total of 6924 screening tests using LDCT were performed.  Baseline positivity rate was 
18%.  The study reported 65 lung cancers, 56 at baseline and 6 at incident screening with 3 
interim cases.  Prevalence was 1.67%.  65% of cancers were stage I at diagnosis and 68% 
were histologically adenocarcinoma. 
Of the 3352 baseline participants, 80% completed at least one annual screen 
demonstrating 20% adherence.  The study does not report on the characteristics of those who 
were lost to follow so there is a concern for selection bias.  The scans were read according to 
the I-ELCAP protocol, but the study does not report any further information about who read 
them.  Overall, quality was rated as fair with fair generalizability.  
Israel – Shaham86  
This prospective study recruited 842 current and former smokers by mixed recruiting 
strategies including physician referral and media recruiting in Israel.  32% were required to pay 
for the screening exam.  Participants were >50 years old with a >10 pack-year smoking history.  
Median age was 56 years old, 57% were male, and median smoking history was 37 pack-years.  
The study did not report the proportion of current to former smokers.  A positive result initially 
followed the I-ELCAP protocol with 1-6 NCN ≥5 mm and then was adjusted during the study to 
1-6 solid or part solid NCN ≥5 mm or non-solid ≥8 mm on baseline and any new NCN or growth 
on repeat scan.  
A total of 1784 screening tests using LDCT were performed.  Baseline positivity rate was 
12%.  The study reported 14 lung cancers, 12 at baseline and 2 at incident screening with no 
interim cases.  Prevalence was 1.43%.  86% of the cancers were stage I at diagnosis and 57% 
were classified as adenocarcinomas. 
Of the 842 participants at baseline, 801 were eligible for repeat screen and 69% of them 
had an annual repeat scan representing a 31% dropout rate for a low adherence rate compared 
to other included studies.  Selection bias is likely to play a significant role here as the study used 
different recruiting strategies and 32% were expected to pay for their exams.  It is possible that 
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those who were required to pay for their exams were more likely to not follow up, however the 
study did not assess differential loss to follow up.  In addition, the study changed the definition 
of a positive result at some point during follow up, however it was not assessed how this 
changed the positivity rate or work up of participants.  All scans were read by a single radiologist 
which could induce systematic interpreting error.  The study changed LDCT slice thickness 
during follow up as well so differential detection of nodules could be affected.  Overall, quality 
was rated as fair with uncertain generalizability.   
DLCST – Pedersen87  
The Danish Lung Cancer Screening Trial (DLCST) is a randomized trial comparing 
LDCT with no screening for lung cancer detection over a period of five years in centers around 
Denmark.  This trial enrolled volunteers recruited via media who were 50-70 years old and had 
a >20 pack-year smoking history.  55% were male and 76% were current smokers.  Of the 5861 
participants who volunteered, 4104 were eligible and randomized.  2052 were assigned to 
receive annual LDCT for five years and 2052 were assigned to receive no screening.  A positive 
screen was defined as any NCN ≥5 mm or any growing nodule.  Only baseline results are 
currently published.  
A total of 2047 LDCT screening tests were performed at baseline.  Baseline positivity 
rate was 8.7%.  The study reported 17 total lung cancers detected in the LDCT arm.  
Prevalence was 0.83%.  53% of the cancers diagnosed were stage I and 71% were 
adenocarcinomas.  
The study reported an adequate randomization procedure with blocks randomized by a 
central system with unknown concealment.  Groups were comparable at baseline for 
demographics.  Five of the participants randomized to the LDCT screening group failed to 
undergo baseline exam for baseline adherence >99%.   It is unclear from the article if crossover 
was assessed.  Scans were read by a 2 radiologists with unknown masking, and discrepancy 
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was resolved by consensus.  I could not determine if blinding was performed for investigators or 
participants.  Quality was rated as fair with fair generalizability.  
Toronto – Roberts89  
The I-ELCAP Toronto prospective study reported by Roberts et al recruited 1000 
volunteers >55 years old with a >10 pack-year history.  Median age was 63 years old, 45% were 
male, and median smoking exposure was 34-38 pack-years.  34% were current smokers and 
66% former smokers.  A positive result was described ≥1 solid/part-solid NCN ≥5 mm or non-
solid ≥8 mm on baseline and any growth or new NCN on repeat screening.  Only baseline 
results were reported.  
A total of 1000 screening tests using LDCT were performed.  Baseline positivity rate was 
26%.  The study reported 20 lung cancers were detected on screening.  Prevalence was 2.0%.  
75% of cancers were stage I at diagnosis and 70% were histologically adenocarcinoma. 
Since the study did not report on repeat screening exams, I could not determine 
adherence to the study protocol.  The scans were interpreted according to the I-ELCAP 
protocol, but the study does not report any further information regarding who or how many 
people provided interpretations.  Masking was not mentioned.  Overall, quality was rated as fair 
with fair generalizability.  
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Appendix D: Discussion 
Prior Systematic Reviews of LDCT screening  
Of the 8 systematic reviews identified in my search strategy, all included a discussion of 
harms of screening, however limited data on harms prevented pooling of results.  Here, I 
individually discuss the evidence and implications of each for screening harms.  
In a short review designed to answer the question of whether screening improves long 
term survival in asymptomatic lung cancer patients, Hunt et al briefly mention false positives and 
overdiagnosis as harms of screening104.  This review included observational studies, had a 
comprehensive search strategy, but did not mention eligibility criteria for articles and did not give 
a quality assessment of included articles.  Thus, it was rated as a poor quality review.  
In a systematic review of the prevalence of incidental findings, Jacobs et al included 
populations undergoing coronary artery disease screening and lung cancer screening using 
CT105.  The authors grouped incidental findings as lesions representing airway disease, renal 
disease, liver disease, breast abnormalities, aortic aneurysm, pericardial disease, pleural 
disease, lymphadenopathy, adrenal mass, gastric tumor, and thyroid disease.  Four primary 
studies were included that screened for lung cancer.  This review found that the mean 
proportion of patients with at least one incidental finding on screening exam was 65.2% (63.5 – 
66.9%).  This represents about two-thirds of those screened who will have an abnormality on 
their screening exam not related to the exam‟s primary purpose.  The authors also found that an 
average of 14.2% (13.2 – 15.2%) of participants in lung cancer screening had further workup for 
an incidental finding.  The authors found that the PALCAD study had the highest rate of 
clinically significant findings with 26.9% ( 22.8 – 31.1%) of those screening undergoing further 
workup for an incidental finding after screening.  The review corroborates my finding that 
variation exists among studies in how they defined an abnormality as clinically relevant.  For 
instance, bronchiectasis and pulmonary fibrosis were included as clinically important in some 
studies72,79, but not in the NELSON study95.  In addition, my conclusion that variation exists in 
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the reporting of incidental findings in lung cancer screening studies is supported by this review.  
In addition to incidental findings, this review discussed false positives, anxiety, and costs of 
workup as harms of screening.  This is a fair quality systematic review as the authors included 
study population characteristics, based their review on a focused key question, had an 
appropriate search, addressed heterogeneity, but did not report a quality assessment of 
included studies.  
In a systematic review of baseline LDCT screening characteristics, Yau and colleagues 
sought to assess current knowledge of LDCT screening to determine if LDCT should be 
introduced for lung cancer screening in a high risk population47.  The authors reported LDCT 
test characteristics including a median sensitivity of 81%, median specificity of 81%, positive 
predictive value of 8%, and negative predictive value of 99%.  Yau reported that 80% of all lung 
cancers detected on screening were stage I NSCLC.  The authors discussed false positives, 
false negatives, anxiety of workup, and costs as harms of screening.  Incidental findings, 
surgery for benign procedures, radiation exposure, and other harms were not mentioned.  This 
review was rated as good as the authors conducted an appropriate search, discussed eligibility 
criteria, sought unpublished data, and used standard methods to assess quality.   
In a systematic review and meta-analysis of baseline findings of randomized trials, 
Gopal et al reported that LDCT screening detects greater numbers of stage I cancers, total 
cancers, and NSCLCs106.  The authors pooled data of 14,055 participants in randomized trials of 
LDCT screening versus a control group (either no screening or CXR).  The odds of detecting a 
Stage I cancer using LDCT was 3.9 (CI: 2.0, 7.4) times as likely as that of the control group and 
the odds of detecting a NSCLC was 5.5 (CI: 3.1, 9.6) times as likely as that of the control group.  
Participants in the LDCT arm were 3.1 (2.6-3.7) times as likely to have a false positive 
screening test compared to controls at baseline.  The authors also reported increased rates of 
unnecessary thoracotomies for benign lesions in the LDCT arm.  The event rate of thoracotomy 
was 3.7 per 1000 screening tests (3.5-3.8) over the study period.  Participants in the LDCT arm 
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were 4 times as likely to have a thoracotomy for a benign lesion as in the control arm.  The 
authors reported that for every 1000 individuals screened, 9 stage I NSCLCs were detected, 
235 false positives occurred, and 4 individuals underwent thoracotomies for benign lesions.  
This fits with my conclusions regarding the high rate of false positives and unnecessary 
surgeries.  The authors also discussed overdiagnosis, further workup, anxiety, and cost as 
harms of screening.   This was a good quality systematic review as the authors included a 
discussion of the study populations, attempted to find unpublished data, included non-English 
trials if available, assessed internal validity of included studies, and addressed heterogeneity in 
control groups.  
In a systematic review of observational studies of LDCT screening, Manser et al 
included 8 observational studies as a component of a larger Cochrane Review107.  This review 
focused on the benefits of screening, but the authors discussed overdiagnosis, cancers missed 
by CT, and benign non-surgical and surgical biopsies.  Conclusions regarding overdiagnosis 
and procedures conducted for benign disease were similar to what I found in the included 
studies in this review.  This review was rated as a fair as the authors conducted an appropriate 
search,  but did not mention an attempt to find unpublished data and it was unclear if non-
English trials included in search.  The authors also did not report an assessment of internal 
validity of included studies and did not assess heterogeneity.    
In a systematic review to evaluate the evidence for lung cancer screening with chest x-
ray, sputum, and LDCT, Humphrey et al included 6 observational LDCT screening studies2.  
The authors concluded that LDCT diagnosed lung cancer at an earlier stage but they were 
unable to determine if a mortality benefit exists.  The authors discussed false positives, false 
negatives, anxiety, overdiagnosis, recommendations for further workup, surgery for benign 
disease, and morbidity and mortality of workup as harms of screening with conclusions that 
were similar to what I found in my review.  This review was rated as good as the authors used 
an appropriate search, included a discussion of eligibility criteria and study populations, and 
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performed a quality assessment but did not report the internal validity of included studies.  It 
was also unclear if the authors attempted to find unpublished data or if non-English trials were 
included.  
In a systematic review to evaluate the evidence for clinical effectiveness of LDCT 
screening, Black et al included 12 studies, 2 of which were short randomized trials3.  The 
authors reported the proportion of people with an abnormal screening result was 5-51% which is 
similar to the positivity rate I report in this review.  The authors mention radiation dose, anxiety, 
false positives, quality of life, and adverse events of screening as harms.  The authors 
concluded that screening harms were poorly reported.  This review was rated as good due to 
the discussion of eligibility criteria and study population, the inclusion of non-English articles, 
and the discussion of the internal validity of the included studies.  
In a systematic review to determine whether LDCT reduces mortality, Bepler et al 
included 8 observational studies4.  The authors included screening related morbidity as a 
secondary outcome and concluded that screening related data were not well reported.  This 
review was rated as fair due to the appropriate search strategy, discussion of reasons for not 
pooling data, eligibility criteria, inclusion of non-English articles in search, and the assessment 
of quality of included studies.    
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Glossary of acronyms: 
NCN: non-calcified nodule 
PLuSS: Pittsburgh Lung Screening Study 
LDCT: low dose computed tomography 
PALCAD: ProActive Lung Cancer Detection study 
LSS: Lung Screening Study 
IF: incidental finding 
DLCST: Danish Lung Cancer Screening Trial 
DANTE: RCT from Milan, Italy group 
CXR: chest x-ray 
ELCAP: Early Lung Cancer Action Project 
NY-ELCAP: New York ELCAP 
I-ELCAP: International ELCAP 
ALCA: Anti-Lung Cancer Association 
ITALUNG: RCT from Florence, Italy group 
PLCO: Prostate, Lung, Colorectal, and Ovarian Cancer study 
NLST: National Lung Screening Trial 
NSCLC: non-small cell lung cancer 
RCT: randomized controlled trial 
 
